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A B S T R A C T
Background
Uncomplicated urinary tract infection (UTI) is a common disease, occurring frequently in young sexually active women. In the past,
seven day antibiotic therapy was recommended while the current practice is to treat uncomplicated UTI for three days.
Objectives
TO compare the efficacy and safety of three-day antibiotic therapy to multi-day therapy (five days or longer) on relief of symptoms
and bacteriuria at short-term and long-term follow-up.
Search strategy
The Cochrane Library (Issue 1, 2004), the Cochrane Renal Group’s Register of trials (July 2003), EMBASE (January 1980 to August
2003), and MEDLINE (January 1966 to August 2003) were searched. We scanned references of all included studies and contacted the
first or corresponding author of included trials and the pharmaceutical companies.
Selection criteria
Randomised controlled trials comparing three-days oral antibiotic therapy with multi-day therapy (five days and longer) for uncom-
plicated cystitis in 18 to 65 years old non-pregnant women without signs of upper UTI.
Data collection and analysis
Data concerning bacteriological and symptomatic failure rates, occurrence of pyelonephritis and adverse effects were extracted inde-
pendently by two reviewers. Relative risk (RR) and their 95% confidence intervals (CI) were estimated. Outcomes were also extracted
by intention-to-treat analysis whenever possible.
Main results
Thirty-two trials (9605 patients) were included. For symptomatic failure rates, no difference between three-day and 5-10 day antibiotic
regimen was seen short-term (RR 1.06, 95% CI 0.88 to 1.28) and long-term follow-up (RR 1.09, 95% CI 0.94 to 1.27). Comparison
of the bacteriological failure rates showed that three-day therapy was less effective than 5-10 day therapy for the short-term follow-
up, however this difference was observed only in the subgroup of trials that used the same antibiotic in the two treatment arms (RR
1.37, 95% CI 1.07 to 1.74, P = 0.01). This difference was more significant at long-term follow-up (RR 1.43, 95% CI 1.19 to 1.73,
P = 0.0002). Adverse effects were significantly more common in the 5-10 day treatment group (RR 0.83, 95% CI 0.74 to 0.93, P =
0.0010). Results were consistent for subgroup and sensitivity analyses.
Authors’ conclusions
Three days of antibiotic therapy is similar to 5-10 days in achieving symptomatic cure during uncomplicated UTI treatment, while
the longer treatment is more effective in obtaining bacteriological cure. In spite of the higher rate of adverse effects, treatment for 5-10
days could be considered for treatment of women in whom eradication of bacteriuria is important.
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P L A I N L A N G U A G E S U M M A R Y
Uncomplicated urinary tract infection (UTI) is a common disease occurring frequently in young women. It is caused by bacteria
multiplying in urine, and the patient usually complains of urgency and burning pain while urinating. The present practice is to treat
the patient with antibiotics for three days. In this review we included all studies that compared three-day therapy with longer treatment
(five days or more). Three days of treatment were adequate to achieve symptomatic relief for most patients, but it appears that longer
therapy is better in terms of bacteria elimination from the urine, no matter what antibiotic is used. Longer therapy for UTI is related to
higher rate of adverse reactions to the antibiotics used. Pending further research, it could be considered for women in whom eradication
of bacteria in the urine is important.
B A C K G R O U N D
Uncomplicated urinary tract infection (UTI) is a common dis-
ease, occurring frequently in young sexually active women. In one
cohort study the incidence of the disease was estimated to be 0.5-
0.7/person-year (Hooton 1996). All over the world the most com-
mon pathogens of uncomplicated UTI are similar: 80-90% Es-
cherichia coli, 5-10% Staphylococcus saprophyticus, the remaining
infections being caused by Proteus spp., and other Gram-negative
rods. Most are bacteria from the gut that colonize the perineum
and then ascend through the urethra to infect the bladder mu-
cosa. The infection causes specific symptoms, mainly the triad
of dysuria (painful urination), urgency (the urgent need to void)
and frequency (very frequent urination). In randomised controlled
trials (RCTs) the diagnosis is based on positive urine cultures in
symptomatic subjects. In the past, the threshold for diagnosis of
UTI was >105 colony forming units (CFU)/ml of voided mid-
stream urine (Stamm 1982). However two decades ago studies
have shown that in young symptomatic women with leucocyturia
even 100 CFU/ml voided midstream urine can establish the diag-
nosis (Stamm 1980; Stamm 1982; Kunin 1993).
A large range of antimicrobials with different rates of cure and side
effects are used in the treatment of UTI. It is thought that a short-
course therapy consisting of a three-day antibacterial regimen is
sufficient for uncomplicated urinary tract infection, as it is prob-
ably as effective as 7-10 days therapy, and may be associated with
less side effects and lower costs (Hooton 1997). Single dose ther-
apy has been advocated for years but about a decade ago reviews
have raised doubts as to its use because of a higher frequency of
bacteriological recurrence (Leibovici 1991; Norrby 1990), and it
is no longer common clinical practice. On the other hand, single-
dose treatment probably achieves symptomatic relief more rapidly
than seven days of treatment (Arav-Boger 1994).
In most clinical trials assessing effectiveness of therapy, cure was
defined as bacteriological cure, rather than symptomatic relief.
Uncomplicated UTI is not considered a serious disease. It is not
clear whether untreated UTI can progress to pyelonephritis, and
if so how often. Progression to pyelonephritis probably occurs at
a very low rate, while asymptomatic bacteriuria in young, healthy
and non-pregnant women is not associated with renal damage
(Stamm 1991).
Thus since our last systematic review on the length of treatment
of uncomplicated UTI in young women (Leibovici 1991), the
following questions arose:
1. What is the relative effectiveness of three days treatment com-
pared with multi-day treatment?
2. Is any difference modified by the antibiotic used (old versus
new) or CFU/ml count?
3. Do persistent positive cultures lead to persistent symptoms?
4. What is the relative effectiveness of single dose and three-day
treatment, compared with seven days treatment, when the out-
come of interest is symptomatic cure rather than bacteriological
one?
5. Does the duration of treatment influence the development of
resistant strains during treatment?
O B J E C T I V E S
The main objective of this review was to assess the evidence, as
found in RCTs for the relative effectiveness of different regimens
of antibacterial treatments in acute, uncomplicated lower urinary
tract infection in otherwise healthy 16 to 65 years old females.
Specific objectives were:
1. To assess the evidence for the relative effectiveness as assessed in
RCT’s comparing three-day versus multi-day therapy on:
a. Relief of symptoms within two weeks after start of treatment (
mostly within seven days)
b. Resolution of bacteriuria within two weeks after start of treat-
ment (bacteriological cure)
c. Recurrence of symptoms or bacteriuria between cure and up-to
eight weeks after start of treatment
d. To assess the frequency of adverse events in the different regi-
mens
2. To assess the evidence for the relative effectiveness of the differ-
ent antibacterial drugs used in the RCTs.
3. To assess the evidence for development of resistance for different
durations of treatment with different drugs (comparing resistance
of grown bacteria before and after therapy).
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C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
We attempted to identify all RCTs comparing the relative effec-
tiveness of three day versus five days or longer oral antibacterial
therapy for uncomplicated UTI in women.
Types of participants
We included studies on ambulatory, otherwise healthy women,
aged 16-65 years, with uncomplicatedUTIdefinedby the presence
of urinary complaints (and by the absence of upper UTI signs);
whenever possible, analysis for the review was limited to women
with positive urine cultures of more than 100 CFU/ml of voided
midstream urine or obtained via urinary catheter.
UncomplicatedUTIwas defined as the absence of all the following:
1. Costovertebral pain or tenderness
2. Fever (more than 37.8 C)
3. Positive blood cultures.




3. Children up to the age of 16 years
4. Hospital acquired infection
5. Pregnancy
6. Indwelling urinary catheter
7. Recent urinary tract instrumentation





Three days oral antibacterial treatment versus antibacterial treat-
ment for five days or more (antibacterial therapy given in both
arms did not have to be identical).
Types of outcome measures
1. Short-term symptomatic failure, defined as persistence or re-
currence of symptoms up to two weeks after starting treatment.
2. Long-term symptomatic failure, defined as persistence or recur-
rence of urinary symptoms up to eight weeks after start of treat-
ment.
3. Short-term bacteriological failure, defined as a positive urine
culture at the first follow-up within two weeks after start of treat-
ment.
4. Long-term bacteriological failure, defined as a positive urine
culture up to eight weeks after start of treatment.
5. Occurrence of pyelonephritis during follow-up.
6. Adverse events:
a. Any serious adverse events that are fatal, life-threatening, or
requiring hospitalisation;
b. Any adverse events that result in significant disability or inca-
pacity;
c. Any important medical events that may not be immediately life-
threatening, or result in death or hospitalisation, but may jeopar-
dize the patient or may require intervention to prevent one of the
above outcomes;
d. Any adverse events that require discontinuation of medication.
e. Adverse events by the involved organs: skin, gastro-intestinal,
vaginal discharge, central nervous system, others.
7. The percentage of pathogens resistant to the study drug two to
eight weeks after start of treatment.
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Renal Group methods used in reviews.
A). The Cochrane Library (Issue 3, 2003), the Cochrane Renal
Group’s Register of trials (July 2003), EMBASE (January 1980 to
August 2003 ), and MEDLINE (January 1966 to August 2003)
were searched with the phrase:
[(urinary near infection*) or cystitis or uti] and [(treatment near
duration) or (single near dos*) or (3 near day*) or (three near
day*)]
We included all languages. By leaving single dose in the search
strategy we found articles that include single and three-day doses
versus multi-day.
B). An additional search was performed in January 2004 with the
assistance of the Trials Search Coordinator (see additional Table
01 - Electronic databases searched)
C). Reference searching and personal contact: The references
of all identified studies were inspected for more studies.
Additionally, the first or corresponding author of each included
study was contacted for complementary information on his own
trial as needed.
M E T H O D S O F T H E R E V I E W
Two reviewers independently inspected each reference identified
by the search and applied the inclusion criteria. For possible
relevant articles, or in cases of disagreement between the
two reviewers, the full article was obtained and inspected
independently by a third reviewer.
Quality assessment
Trials fulfilling the review inclusion criteria were assessed for
methodological quality by two reviewers. This was done using the
criteria described in theCochraneHandbook (Clarke 1999), based
on the evidence of a strong association between poor allocation
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concealment and overestimation of effect (Schulz 1995) and
defined as below:
Allocation concealment
A. Low risk of bias (adequate allocation concealment)
B. Moderate risk of bias (some doubt about the allocation
concealment)
C. High risk of bias (inadequate allocation concealment)
For the purpose of the analyses in this review, trials were included
if they meet the criteria A or B in the Handbook (Clarke 1999;
Kunz 1998).
Intention-to-treat (ITT) analysis
ITT analysis was performed regarding all dropouts in study as
failures to achieve symptomatic or bacteriological cure. Whenever
possible, we regarded only the patients with positive urine cultures
(significant bacteriuria) as the reference total patient number in
the two study arms. When the numbers of randomised women
with positive cultures in the study groups was unavailable, the total
number of randomised patients was taken for performing the ITT
analysis for symptomatic short-term and long-term failures, but
not for the bacteriologic outcomes.
Data collection
Two reviewers independently extracted the data of included trials.
Trials were identified by the name of the first author and year in
which the trial was first published and ordered chronologically.
The following data will be extracted, checked and recorded:
(i) Characteristics of trials
* Date, location, period of data collection, year of publication;
* Publication status;
* Case definitions (symptomatic, bacteriological, both)
* Bacteriologic definition (105 or 102 CFU/ml)
* Sponsor of trial (commercial, academic, pharmaceutical, or
unknown)
* Blinding
* Allocation concealment (yes, no and method)
* Definitions of cure (symptomatic, bacteriological or both)
(ii) Characteristics of participants
* Number of participants in each group;
* Age (as described in the article: mean, median or range);
(iii) Characteristics of interventions
* Type, dose and duration of antibacterial therapy;
(iv) Characteristics of outcome measures
* No of patients with bacteriological cure (as defined above) in
each group;
* No of patients with symptomatic recurrence (as defined above)
in each group, divided into local and systemic recurrences;
* No of patients with bacteriological recurrence (as defined above)
in each group;
* No of patients with adverse reactions, per type and total;
* No of patients with resistant microorganisms, as defined above;
* Lost to each follow-up (dropouts) before end of study.
Data synthesis
Dichotomous data was analysed by calculating the relative
risk (RR) for each trial with the uncertainty in each result
being expressed using 95% confidence intervals (CI). Whenever
comparisons made between the mean duration of symptoms in
the two groups were normally distributed, these continuous data
were analysed by using the mean and standard deviation of each
trial and calculating the effect size (average mean difference) and
the 95% CI.
Heterogeneity and publication bias
Heterogeneity in the results of the trials was initially assessed by
inspection of graphical presentations and by calculating a test
of heterogeneity (Chi2 and I2 - Higgins 2003). We anticipated
between-trial variation in estimation of morbidity for those
patients who were treated with different antibiotics. Subgroup
analyses were performed in order to assess the impact of this
possible source of heterogeneity in themain results. The following
factors were checked: allocation generation and concealment
methods, different antibiotics groups (quinolones, beta-lactams
etc), per cent of dropouts in the studies.
A funnel plot estimating the precision of trials (plots of RR for
efficacy against the sample size) was examined in order to estimate
potential asymmetry. A fixed effect model was used throughout
the review, except in the event of significant heterogeneity between
the trials (P < 0.10), when the random effect model was chosen.
D E S C R I P T I O N O F S T U D I E S
The computerised search strategy identified a large number of
publications comparing different regimens of antibiotic therapy
forUTI, not all relevant for the present review.Thesewere screened
for RCTs, uncomplicated UTIs, antibiotics treatment duration
and presence of exclusion criteria. Of 56 trials obtained this way
24 were excluded for different reasons (seeTable of excluded studies)
while 32 RCTs were considered eligible for this review.
Two reports were identified as duplicate publications and are con-
sidered under their primary reference (Sandberg 1985). Five pub-
lications were found to be case-control or non randomised studies
(Bargelloni 1972; Furusawa 1994; Hoigne 1977; Liudvig 1996;
Loran 1997), while five others were reviews of different trials of
which several were included in the analysis (Blomer 1986; Hooton
1989; Iravani 1991; Iravani 1995; Vogel 1984). Eight RCTs com-
pared two different antibiotic regimens of at least five days dura-
tion (Bailey 1983; Fancourt 1984; Hill 1985; Little 1979; Martin
1983; McCarthy 1972; Pelta 1985; Zorbas 1995), two additional
trials were excluded for they compared a single-dose antibiotic to
ten-day (Schultz 1984) or three-day (Gellerman 1988) regimen.
Another trial reported only clinical improvement but not cure
(Ishihara 1998). One further study was excluded because it in-
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cluded only elderly postmenopausal women (mean age 66 ±20)
(Raz 1996). Two trials were excluded as they appeared to be quasi-
randomised or criterion C in the Handbook (Charlton 1976; Fair
1980).
Thirty-two trials were included in the review (see Table of included
studies). One trial compared two different antibiotics with sub-
groups of three-day and ten-day treatment regimens in each, and
the results for these two drugs were regarded separately as two dif-
ferent trials (Gordin 1987a; Gordin 1987b).
The contact authors of these 32 included and two excluded as
quasi-RCTs (Charlton 1976; Fair 1980) were contacted (by mail
and if possible by e-mail) of whom 10 replied. Unpublished data
were obtained for seven studies.
Patient characteristics
The included studies were performed between the years 1980-
2002 and included 9605 randomised patients. The median num-
ber of patients/trial was 300.
In six trials (1356 patients) men were included (Basista 1991; Cox
1992; Hansen 1981; Menday 2000; Rapoport 1981; Stein 1987).
Their number was less than 10% in each study group and it was
impossible to separate the results for men and women for any of
these trials. One additional trial (Bitsch 1985) included men, but
analysis of men and women was separated and only data regarding
women was used for this review.
Fourteen studies included women above 65 years of age (Basista
1991; Bitsch 1985; Cox 1992; Guibert 1997; Hansen 1981; Inter-
nordic 1988; Iravani 1999; Menday 2000; Piipo 1990; Rapoport
1981; Sandberg 1985; Stein 1987; Stein 1992; Tsugawa 1999).
In all these 14 trials patients above 65 years made up the minority
of the study groups and in 7 of these trials the mean age reported
(33 to 45 years) was well below the upper limit we defined for this
review (Basista 1991; Bitsch 1985; Guibert 1997; Hansen 1981;
Rapoport 1981; Sandberg 1985; Stein 1992). Unfortunately, it
was impossible to analyse data for patients below and above the
age of 65 separately.
Nearly all trials defined bacteriuria as more than 105 CFU/ml for
any bacteria or the same concentration for Gram-negative bacte-
ria and 104 CFU/ml for Staphylococcus. Several studies included
patients with lower urine bacteria concentration of 104 CFU/ml
(Hovelius 1985; Neringer 1992; Stein 1992; Tsugawa 1999), 103
CFU/ml (Iravani 1999) and 102 CFU/ml (Hooton 1991) for any
bacteria. In one trial, positive urine culture was not necessary for
patient inclusion and the case definition was based on the clinical
signs and pathologic urinalysis (Guibert 1997).
In two trials several women with asymptomatic bacteriuria were
treated and taken into account for the bacterial cure results (Gordin
1987a; Gordin 1987b; Hooton 1991).
Antibiotic regimens
The same antibiotics in the three-day and 5-10 day groups were
used in 19 trials, of these quinolones were used in six trials
(Garcia 2002; Internordic 1988; Neringer 1992; Piipo 1990;
Trienekens 1993; Tsugawa 1999), beta-lactams in eight (Gordin
1987b; Greenberg 1986; Hansen 1981; Hovelius 1985; Marsh
1980; Pitkajarvi 1990; Richards 1984; Sandberg 1985) and dif-
ferent combinations of sulfonamides and trimethoprim in five tri-
als (Gordin 1987a; Gossius 1984; Gossius 1985; Iravani 1983;
Trienekens 1989). In one of these studies different doses of the
same antibiotic drug (pivmecillinam) were used in the two study
groups (Hansen 1981).
Fourteen trials compared different antibiotics given in the three-
day and in the 5-10 day groups. The drug in the three-day group
was a quinolone in nearly all of these studies, and was compared
to 5-10 day regimens of beta-lactam (Winwick 1981), different
combinations of sulfonamides and trimethoprim (Basista 1991;
Bitsch 1985; Butler 1983; Cox 1992; Hooton 1991; Stein 1987),
another quinolone (Henry 1999; Guibert 1997; Stein 1992) or a
combination of nitrofurantoin with trimethoprim-sulfamethoxa-
zole (Iravani 1999).One additional trial compared three-day treat-
ment with trimethoprim-sulfamethoxazole to seven-day treatment
with any of a long list of antibiotics (Rapoport 1981). In two trials
three-day therapy with beta-lactam was compared to seven-day
treatment with another drug of the beta-lactam group (Menday
2000) or trimethoprim-sulfamethoxazole (Figueroa 1999).
M E T H O D O L O G I C A L Q U A L I T Y
Randomisation and allocation concealment
Adequate allocation concealment, using sealed envelopes or cen-
tral randomisation, was described in 12 trials (Basista 1991;
Bitsch 1985; Gordin 1987a; Gordin 1987b; Henry 1999; Hooton
1991; Hovelius 1985; Iravani 1999; Neringer 1992; Piipo 1990;
Richards 1984; Sandberg 1985; Trienekens 1993). Allocation gen-
eration was adequate in all 12 and in additional six (Butler 1983;
Gossius 1985; Marsh 1980; Pitkajarvi 1990; Stein 1987; Stein
1992). These studies used computer-generated lists or predeter-
mined randomised codes. Randomisation methods were not de-
scribed in all other trials.
Blinding
Ten trials were double-blinded (Henry 1999; Internordic 1988;
Iravani 1999; Menday 2000; Neringer 1992; Piipo 1990; Stein
1992; Trienekens 1989; Trienekens 1993; Tsugawa 1999), one
single-blinded (Richards 1984) and the remaining open RCTs.
ITT analysis
ITT analysis was presented in only two of the 32 trials included
for treatment failure (Henry 1999; Iravani 1999). Dropouts and
numbers of patients with positive urine cultures were reported by
their allocation group in 21 of 32 trials presenting per protocol
analysis for treatment failure, permitting a second ITT analysis
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assuming dropouts as failures. The number of patients excluded
from the analysis at the first follow-up ranged between 0-20%
for bacteriological cure outcome and 0-26% for clinical (symp-
tomatic) cure; at the second follow-up these numbers were 0-29%
and 6-45%, respectively.
The first follow-up was performed between two to 15 days from
the end of the treatment (short-term), and the second follow-up
was performed four to 10 weeks from the treatment (long-term).
R E S U L T S
Trials were divided into two major subgroups: those with the same





Assessment of short-term symptomatic failure rate was possible in
24 trials (8752 patients). Data for efficacy analysis was available in
5165 patients. No significant difference between three-day and 5-
10 day antibiotic treatment was observed (outcome 01: RR 1.06,
95%CI0.0.88 to 1.28, P =0.52), with no significant heterogeneity
observed for this comparison (Chi2 = 27.14, df = 23, P = 0.25, I2
= 15.3%)
Separate analysis of trials with same or different antibiotic in the
two treatment arms showed no significant difference. In 14 trials
comparing the same antibiotic the RR was 1.15 (95% CI 0.95 to
1.39, outcome 01.01) in 10 trials with different antibiotics the RR
was 0.90 (95% CI 0.62 to 1.29, outcome 01.02). No differences
were shown after performing subgroup analyses for the factors:
antibiotic classes (quinolones, beta-lactams, sulfonylamides with
orwithout trimethoprim); allocation generation and concealment;
or per cent of dropouts.
Long-term
Assessment of long-term symptomatic failure rate was available
from eight trials (3141 patients). No difference was found between
the two arms (outcome 03: RR 1.09, 95% CI 0.94 to 1.27). After
performing subgroup analysis as for the first follow-up results no
differences were shown.
A secondary ITT analysis counting dropouts as failures of treat-
ment showed similar results (outcomes 02 and 04).
Bacteriologic failure
Short-term
Assessment of short-term bacteriological failure rate was possible
in 31 trials (8874 patients). For efficacy analysis 5368 patients
were included, the majority of the excluded persons having neg-
ative urine cultures after being allocated to one of the study regi-
mens. Five to 10-day antibiotic regimen appeared to be superior
to the three-day regimen although the result was not significant
using the random effects model (outcome 05: RR 1.19, 95% CI
0.98 to 1.44, P = 0.08), but just significant with the fixed effect
model (RR 1.20, 95% CI 1.00 to 1.44, P = 0.05). No significant
heterogeneity was observed for this comparison (Chi2 = 24.54,
df = 29, P=0.70, I2 = 0%). This advantage was observed in trials
comparing the same antibiotic (outcome 05.01: RR 1.37, 95%CI
1.07 to 1.74; P = 0.01), and absent in the subgroup analysis of tri-
als comparing different drugs (RR 0.96, 95% CI 00.68 to 1.35, P
= 0.80). The trials using same antibiotic drug in the two treatment
arms was further divided for subgroup analysis based on the dif-
ferent antibiotic classes (outcome 06) and showed that the results
were not significantly influenced by the drug choice. The results
remain unchanged after performing the other subgroup analyses
(for allocation generation and concealment class, trial size or per
cent of dropouts).
A secondary ITT analysis for the short-term results was only pos-
sible in 21/31 trials. Its results showed actually no difference be-
tween the two treatment regimens, (outcome 07: RR 0.92, 95%
CI 0.80 to 1.06). No difference was observed in any of the sub-
groups analyses.
Long-term
Assessment of the long-term bacteriological failure rate was possi-
ble in 18 trials (3715 patients) (13 trials and 2502 patients in the
same antibiotic subgroup; five trials and 1213 patients in the dif-
ferent regimens subgroup). The 5-10-day antibiotic regimen was
superior to the three-day regimen (outcome 08: RR 1.31, 95%
CI 1.08 to 1.60, P = 0.006) and no significant heterogeneity was
observed (Chi2 = 24.40, df = 17, P = 0.11, I2 = 30.3%). A sig-
nificant difference was shown in the subgroup of trials with the
same drug in both allocation arms (outcome 08.01: RR 1.43, 95%
CI 1.19 to 1.73, P = 0.0002), while no difference was observed
between 5-10 day and three day regimens when different drugs
were used. These results also remain unchanged after performing
the additional subgroup analyses for antibiotic class (outcome 09),
allocation generation, trial size and concealment class or per cent
of dropouts.
A secondary ITT analysis for the second follow-up results showed
the same results as the efficacy analysis, confirming the observed
significant advantage of 5-10day antibiotic regimenover the three-
day regimen for all trials (outcome 10: RR 1.19, 95% CI 1.06 to
1.35, P = 0.004), and for the subgroup of the same drug regimen
(outcome 10.01: RR 1.26, 95% CI 1.08 to 1.47, P = 0.003). The
results of the subgroup analysis for the class of antibiotic drug are
shown in outcome 11.
Pyelonephritis
Only five of the included trials reported the incidence of
pyelonephritis (Cox 1992; Gossius 1984; Gossius 1985; Hovelius
1985; Winwick 1981). Only two cases of pyelonephritis were re-
ported, both in the three-days therapy groups (Gossius 1984; Gos-
sius 1985). As this outcome was extremely uncommon in the pop-
ulation of young women with uncomplicated lower UTI, no dif-
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ference could be observed between the two treatment regimens
(outcome 13).
Adverse effects
All side effects were observed more frequently in the 5-10 day reg-
imen than in the three-day group. The risk for the development
of any side effect during therapy was 17% lower in the three-
day group (outcome 12: RR 0.83, 95% CI 0.74 to 0.93, P =
0.0010). This difference was more prominent in trials comparing
the same antibiotic (outcome 12.01: RR 0.76, 95% CI 0.63 to
0.92) and especially when the drug was sulfonylamide/trimetho-
prim (outcome 20: RR 0.40, 95% CI 0.19 to 0.88).
A substantially lower percentage of patients had to discontinue
therapy in the three-day group, (outcome 14: RR 0.51, 95% CI
0.328 to 0.91, P = 0.02), particularly when the same drug was
given in the two groups (outcome 14.01: RR 0.35, 95% CI 0.12
to 0.98, P = 0.04).
Gastrointestinal side effects appeared less frequently during three-
day treatment (outcome 15: RR 0.81, 95% CI 0.67 to 0.94, P
= 0.02). The difference in the frequency of development a skin
rash was significant in the trials comparing the same antibiotic
(outcome 16.01: RR 0.51,95% CI 0.33 to 0.77, P = 0.002), while
no such difference was observed in the trials with different drugs
(outcome 16.02: RR 0.69, 95% CI 0.21 to 2.28). The rate of side
effects related to central nervous system was also slightly more fre-
quent in the 5-10 day group, but this difference was not significant
overall (outcome 17: RR 0.83, 95% CI 0.65 to 1.06, P = 0.13).
As for anaphylactic reactions, only two trials described one case,
both in the 5-10 day group (Butler 1983; Gossius 1984), and no
difference could be observed between the two treatment regimens.
Resistant organisms
Only a minority of the included trials described the antibiotic re-
sistance profile of the bacteria cultured from patients urine before
and after treatment. In two studies using quinolones in both treat-
ment arms, no persistent or recurrent pathogen developed resis-
tance to the study drugs during treatment or during the follow-
up period (Internordic 1988; Neringer 1992). In one trial study-
ing thee-day versus seven-day pivmecillinam regimens (Richards
1984) the number of resistant bacteria isolates after therapy did
not change, and an additional trial using the same drug (Hansen
1981) showed only total rate of resistance development after ther-
apy without specification to different study groups. Two studies
using sulfonamide (Iravani 1983) and co-trimoxazole (Trienekens
1989) mentioned the prevalence of the drug-resistant E. coli in the
failure cases, but it was unclear whether these were primary resis-
tant strains or the resistance developed during the treatment. One
study (Basista 1991) showed significant difference in the develop-
ment of urine bacteria resistance between the three-day (no cases)
and the seven-day (three cases) protocols but the drugs used in
the two treatment arms were different (quinolone versus trimetho-
prim/sulfamethoxazole), so this data is of only limited value.
Dropouts and selection bias
Funnel plots for symptomatic (Figure 01 - Funnel plot symptomatic
failure) and bacteriological failure (Figure 02 - Funnel plot bacte-
riologic failure ) showed that several smaller studies favouring the
three-day regimen may be missing from this review. It is impor-
tant to mention that all the studies included in this meta-analysis
were planned to check the hypothesis that the three-day antibiotic
therapy is as effective as a longer one.
The number of patients excluded from each study arm was nearly
equal, both for symptomatic and bacteriological outcomes assess-
ment.
D I S C U S S I O N
Thirty-two RCTs, including 9605 patients, comparing three-day
antibiotic treatment to 5-10 day treatment for the empirical ther-
apy of uncomplicated UTIs in the young andmiddle-aged women
were analysed. Two outcomes were chosen for comparison: symp-
tomatic failure and bacteriological failure as defined by positive
post-treatment urine cultures. Primary treatment failures and re-
currences or re-infections were considered together as therapy fail-
ures, for in the majority of the studies no distinction could be
made between them.
Symptomatic failure rates did not differ significantly both in the
short-term (RR 1.06, 95% CI 0.88 to 1.28) or long-term (RR
1.07, 95% CI 0.99 to 1.16) after treatment with three-day or 5-
10 day regimens. No information about the timing of the symp-
tomatic cure could be found in the included studies.
Five to 10 day antibiotic regimen was more effective than three
day therapy, keeping the patients’ urine sterile two to 15 days af-
ter the end of treatment (same drug therapy RR 1.37, 95% CI
1.07 to 1.74, P = 0.01). This means that 41 women would have
to be treated for seven days to prevent one case of recurrence or
persistence of bacteriuria for a short period. The ITT analysis
showed no difference between short and long treatment regimens.
Data considering the numbers of randomised patients with posi-
tive urine cultures were unattainable from the published articles or
any additional source in six major studies in this subgroup (Garcia
2002; Gossius 1984; Gossius 1985; Marsh 1980; Richards 1984;
Trienekens 1993), so it was impossible to include these trials into
the ITT analysis. This fact, together with the high rate of dropouts,
could explain why we failed to show a significant effect of therapy
duration on the short-term bacteriologic failure rates in the ITT
analysis.
A larger advantage of 5-10 day over three-day antibiotic therapy
in preventing bacteriological failure was observed after 4-10 weeks
(RR 1.43, 95%CI 1.19 to 1.73, P = 0.0002) when treatment with
the same drugwas compared (number needed to treat (NNT) = 4).
This difference remained significant also with an ITT analysis (RR
1.26, 95% CI 1.08 to 1.47, P = 0.003). It is important to mention
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that the advantage of the longer therapy in terms of bacteriological
success appeared to be independent of the antibiotic class chosen
for UTI treatment including quinolones.
One reason for the advantage of longer therapy might be the sur-
vival of bacteria in subepithelial loci of the lower urinary tract
after a shorter course of antibiotic treatment. Recently the abil-
ity of E. coli to invade epithelial cells and create biofilms with
pod-like bulges on the bladder surface was discovered (Anderson
2003). These pods contain bacteria encased in a polysaccharide-
rich matrix surrounded by a protective shell of uroplakin, and al-
low bladder infections to persist in the face of robust host defences
and short-term antibiotic treatment. Another recently published
study showed that asymptomatic bacteriuria is associated with an
increased risk of symptomatic UTI in young women (Hooton
2000). Thus, bacteriological failure might also carry a clinical sig-
nificance for the patients.
The probable cause for the absence of such difference in the trials
comparing different drugs in the two study groups was the fact
that all but three of these trials compared three-day quinolone
therapy with 5-10 day regimen of beta-lactams or sulfonylamides/
trimethoprim. Both the higher urine concentration and the lower
rate of bacteria drug resistance favoured the newer quinolones.
When trying to answer the question concerning the optimal treat-
ment duration for UTI one should probably consider trials com-
paring the same drug in the two therapy groups.
We found a discrepancy between symptomatic cure, whichwas not
influenced by treatment duration, and bacteriological cure. Fewer
included trials showed results of symptomatic cure as compared
to bacteriologic results (21 versus 31 studies at the first follow-
up and 10 versus 18 at the second follow-up, respectively). This
could be one of the reasons explaining the discrepancy between
the efficacy results for these two outcomes.
Not surprisingly, the cost of the higher bacteriological cure rates
after longer antibiotic therapy is a significantly higher rate of ad-
verse events, including those leading to treatment discontinuation.
Again, the difference was observed in the trials dealing with two
regimens of the same drug. The per cent of patients who stopped
the treatment because of adverse effects in the three-day group was
1.5% compared to 3.2% in the 5-10 day group (RR 0.35, 95%CI
0.12 to 0.98, P = 0.04), number needed to harm = 79. However
all adverse effects were minor.
We performed sensitivity analyses that did not detect sources of
bias originating in studies‘design, methodology or class of antibi-
otic drug used. However, allocation concealment was known to
be adequate in only 12 of included 31 trials, and only 11 were
blinded. All but two of the included studies did not adhere to the
principle of ITT analysis. Larger numbers of patients excluded
from the efficacy analysis was due to negative urine cultures after
admission, which should be considered as exclusions rather than
dropouts, but the high rate of dropouts during the follow-up was
a major problem in many included studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The present practice of treating uncomplicated UTIs in young
women for only three days to achieve symptomatic relief is prob-
ably sufficient for the majority of patients. However it leaves a
significant risk of recurrent or persistent bacteriuria independent
of the class of the drug.
Pending further research, antibiotic treatment for 5-10 days could
be considered for women in whom bacteriological eradication
might be of importance: e.g. women suffering from recurrent and
painful lower UTIs, planning pregnancy or with underlying dis-
orders. Ultimately the decision regarding therapy duration should
be takenwith the patient, balancing the higher bacteriological cure
rate versus the similar symptomatic outcome and increased risk
for adverse events.
The risk of pyelonephritis development as a function of therapy
duration is probably irrelevant as it is an extremely rare event in
patients with lower UTI.
Implications for research
We propose that future research in this area should address the
question of the link between the bacteriuria and symptomatic
UTIs. Future trials should use the same antibiotic drug in the dif-
ferent treatment duration groups to exclude the effect of antibiotic
efficacy. It is important to perform antibiotic susceptibility tests
during the follow-up to assess whether duration of the antibiotic
therapy influences the rate of resistance development.
The duration of treatment in special groups of women (i.e. those
suffering from recurrent and painful lower UTIs, planning preg-
nancy, or with underlying disorders) should be addressed in fur-
ther studies.
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Interim analysis: no information
Excluded for efficacy analysis: 40/97 patients (19+21) - 25 of them (14+11) due to negative urine cultures
Excluded for safety analysis: 3/97 (2+1)
Follow-up: 4 to 10 days after treatment
Participants USA (8 centers)
97 patients (over 90% - female and white)
Age: 18-84 (mean = 33)
Data collection: no information
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Characteristics of included studies (Continued )
Bacteriuria > 10ˆ5 CFU/ml
Interventions ofloxacin 200 mg x 1 for 3 days
vs
TMP-SMX 160/800 mg x 2 for 7 days
Outcomes Clinical cure (but results not shown)
Bacteriological cure
Adverse effects
Notes 90% - female and white (the exact number of males not mentioned)
Age: 18-84
The trial was terminated early by the sponsor’s medical monitor after 97 patients (instead of 150) involved
Different antibiotics were compared
Allocation concealment A – Adequate
Study Bitsch 1985
Methods Randomisation: sealed envelopes method
Blinding: no information
Intention-to-treat: no information
Interim analysis: no information
Excluded: 84/394 (30 - no urine cultures was taken; 41 - no significant bacteriuria; 13 - dropouts)
Follow-up : 2 days and 10 weeks after end of treatment
Participants Denmark
394 patients (92% - non-pregnant women)
Age: 16-70 (mean = 38)
Data collection: 5/81 - 5/82
Bacteriuria > 10ˆ5 CFU/ml
Interventions pivmecillinam 400 mg x 3 for 3 days
vs




Notes ~8% (25 of 310 included in efficacy analysis) were males but results for women with uncomplicated lower
UTI only can be separated
Different antibiotics were compared
Allocation concealment A – Adequate
Study Butler 1983
Methods Randomisation: randomised list
Blinding: no information
Intention-to-treat: no information
Interim analysis: no information
Excluded for clinical efficacy: 16/141 (12 - lost to follow-up; 3 - stopped treatment due to side effects; 1 -
admitted to hospital due to gastritis)
Excluded for bacteriological efficacy analysis: 75/141 (no significant bacteriuria)
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Characteristics of included studies (Continued )
Data collection: no information Bacteriuria > 10ˆ5 CFU/ml
Interventions nalidixic acid 660 mg + sodium citrate 3.75 g x 3 for 3 days
vs
TMP/SMX 160/800 mg x 2 for 5 days
Outcomes Clinical cure
Bacteriological cure
Notes Different antibiotics were compared
Allocation concealment B – Unclear
Study Cox 1992
Methods Randomisation: no information
Blinding: no information
Intention-to-treat: no information
Interim analysis: no information
Excluded for efficacy analysis: 65/202 (39 - diagnosis not confirmed; 9 - resistance or intermediate sensitivity
in TMP/SMX group; 7 - no compliance to treatment; 6 - lost to follow-up; 4 - reasons not reported)
Excluded for safety analysis: 2/202 patients
Follow-up: 5-9 days after treatment
Participants USA
202 patients
Males: 3 of 137 finally analysed
Age: 18-80 (female)
37-46 (male)
Data collection: 2/88 - 10/88
Bacteriuria > 10ˆ5 CFU/ml
Interventions ofloxacin 200 mg x 1 for 3 days
vs




Notes Males not excluded
Age of females: 18-80
Different antibiotics were compared
Allocation concealment B – Unclear
Study Figueroa 1999
Methods Randomisation: no information
Blinding: No
Intention-to-treat: no information
Interim analysis: no information
Follow-up: 7-10 days and 21-28 days after treatment
Participants Mexico
60 non-pregnant women
Age: 18 - 50
Bacteriuria > 10ˆ5 CFU/ml
Data collection: no information
Interventions ceftibuten 400 mg single dose
vs
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Characteristics of included studies (Continued )
ceftibuten 400 mg x 1 for 3 days
vs




Notes Different antibiotics were compared
Additional group of patients was studied - a single-dose of ceftibuten
Only short-term results shown
Allocation concealment B – Unclear
Study Garcia 2002
Methods Randomisation: no information
Blinding: no information
Intention-to-treat: no information
Interim analysis: no information
Excluded for efficacy analysis: 33/151 (5 - bacteria resistant to norfloxacin; 12 - negative cultures; 16 - lost
for follow-up)




Data collection: 1998 - 1999
Bacteriuria > 10ˆ5 CFU/ml
Interventions norfloxacin 400 mg x 2 for 3 days
vs
norfloxacin 400 mg x 2 for 7 days
Outcomes Clinical cure
Bacteriological cure
Notes Upper age limit not mentioned
Only short-term results shown
Allocation concealment B – Unclear
Study Gordin 1987a
Methods Randomisation: latin square method
Blinding: No
Intention-to-treat: no information
Interim analysis: no information
Excluded to efficacy analysis: 27/159 (20- negative urine cultures; 4- lost to follow-up; 3- discontinued
treatment due to side effects)
Follow-up : 3-5 days and 4 weeks after treatment
Participants Finland
159 women
Age : 17-63 (mean = 32)
Data collection : 9/82 - 10/84
Bacteriuria > 10ˆ5 CFU/ml
Interventions TMP-sulfadiazine(160mg+500mg) x 2 for 3 days
vs
TMP-sulfadiazine(160mg+500mg) x 2 for 10 days
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Characteristics of included studies (Continued )
Outcomes Bacteriological cure
Adverse effects
Notes 7 of 159 - patients with asymptomatic bacteriuria included
A trial with 4 groups was analysed as two separate subtrials
Allocation concealment A – Adequate
Study Gordin 1987b
Methods Randomisation: latin square method
Blinding: No
Intention-to-treat: no information
Interim analysis: no information
Excluded to efficacy analysis: 27/159 (20- negative urine cultures; 4- lost to follow-up; 3- discontinued
treatment due to side effects)
Follow-up: 3-5 days and 4 weeks after treatment
Participants Finland
159 women
Age: 17-63 (mean = 32)
Data collection : 9/82 - 10/84
Bacteriuria > 10ˆ5 CFU/ml
Interventions pivmecillinam 200mg x 3 for 3 days
vs
pivmecillinam 200mg x 3 for 10 days
Outcomes Bacteriological cure
Adverse effects
Notes 7 of 159 - patients with asymptomatic bacteriuria included
A trial with 4 groups was analysed as two separate subtrials
Allocation concealment A – Adequate
Study Gossius 1984
Methods Randomisation: no information
Blinding: no information
Intention-to-treat: no information
Interim analysis: no information
Excluded - 185/464 (143 - negative cultures; 7 - resistant organisms; 11 - lost to follow up; 24 - adverse
reactions necessitated cessation of treatment)
(Side effects assessed in 408 patients)




Data collection: no information
Bacteriuria > 10ˆ5 CFU/ml
Interventions TMP-SMX (160mg+800mg) x 2 for 3 days
vs
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Characteristics of included studies (Continued )
Notes Additional group of patients was studied - a single-dose TMP-SMX
Allocation concealment B – Unclear
Study Gossius 1985
Methods Randomisation: boxes with code numbers and tablets wrapped in plain alluminium foil
Blinding: no information
Intention-to-treat: no information
Interim analysis: no information
Excluded: 63/135 (44 - nonsignificant pre-therapy bacteriuria; 6 - lost to follow up; 2 - initially resistant
organisms; 1 - developed pyelonephritis(in 3-day group); 7 - side effects leading to therapy cessation)
Follow-up: 2 and 6 weeks after treatment
Participants Norway
135 women
Age: 16 to 60
Data collection: no information
Bacteriuria > 10ˆ5 CFU/ml
Interventions TMP 200 mg x 2 for 3 days
vs
TMP 200 mg x 2 for 10 days
Outcomes Clinical cure
Bacteriological cure
Adverse effects (for 114 patients who completed treatment)
Notes Clinical response for patients without significant bacteriuria mentioned for total number (not devided for
the treatment groups)
Allocation concealment B – Unclear
Study Greenberg 1986
Methods Randomisation: no information
Blinding: no information
Intention-to-treat: no information
Interim analysis: no information
Excluded: 15/126 at 3-days follow-up visit ; 49/126 at 2-weeks follow-up visit




Data collection: 4/83 - 11/84
Bacteriuria > 10ˆ5 CFU/ml
Interventions cefadroxil 1 g single dose
vs
cefadroxil 500 mg x 2 for 3 days
vs
cefadroxil 500 mg x 2 for 7 days
vs
TMP/SMX 320/1600 mg single dose
vs
TMP/SMX 160/800 mg x 2 for 3 days
Outcomes Clinical cure
Bacteriological cure
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Characteristics of included studies (Continued )
Adverse effects
Notes Different antibiotics were compared
Two additional groups of single dose treatment
Only two groups (cefadroxil 500 mg x 2 for 3 vs 7 days) will be analysed here
Allocation concealment B – Unclear
Study Guibert 1997
Methods Randomisation: no information
Blinding: no information
Intention-to-treat: yes
Interim analysis: no information
Follow-up: 14 days after end of treatment





Bacteriuria: not defined (case definition by clinical signs and symptoms)
Interventions lomefloxacin 400 mg x 1 for 3 days
vs
norfloxacin 400 mg x 2 for 10 days
Outcomes Clinical cure
Adverse effects
Notes Different antibiotics were compared
Bacteriuria: not defined
Allocation concealment B – Unclear
Study Hansen 1981
Methods Randomisation: no information
Blinding: no information
Intention-to-treat: no information
Interim analysis: no information
Follow-up: 2 days and 8-10 weeks after end of treatment
Participants Denmark
221 patients
Women - 92% (non-pregnant)
Age: 16-80 (mean = 39)
Data collection: no information
Bacteriuria > 10ˆ5 CFU/ml
Interventions pivmecillinam 400 mg x 3 for 3 days
vs
pivmecillinam 200 mg x 3 for 7 days
Outcomes Bacteriological cure
Adverse effects
Notes 8% - males
Different antibiotic doses were compared
Multicenter trial
Allocation concealment B – Unclear
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Characteristics of included studies (Continued )
Study Henry 1999
Methods Randomisation: allocation numbers generated by the pharmaceutic company; cards with the listing of the
medication distributed to the centers
Blinding: double-blinded, double-dummy
Intention-to-treat: Yes
Interim analysis : no information
Excluded to clinical efficacy analysis: 221/1175
Excluded to bacteriological efficacy analysis: 685/1175




Data collection: 1/94 - 2/95
Bacteriuria > 10ˆ5 CFU/ml
Interventions sparfloxacin 400 mg single dose
vs
sparfloxacin 400 mg on the first day followed by 200 mg x 1 (3 days total)
vs





Additional group of single-dose drug
Higher percentage of patients with previous urinary tract surgery in the 7-day group
More drop-out in the 7-day group than in 2 other groups
Different antibiotics were compared
Allocation concealment A – Adequate
Study Hooton 1991




Interim analysis: no information
Excluded to efficacy analysis: 6/150 (5 - no significant bacteriuria; 1 - no follow-up)




Data collection : no information
Bacteriuria > 10ˆ2 CFU/ml with symptoms or Bacteriuria > 10ˆ5 CFU/ml asymptomatic
Interventions ofloxacin 400 mg single dose
vs
ofloxacin 200 mg x 1 for 3 days
vs
TMP/SMX 160/800 mg x 2 for 7 days
Outcomes Bacteriological cure
Adverse effects
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Characteristics of included studies (Continued )
Notes Significant bacteriuria defined as > 10ˆ2 CFU/ml + symptoms or pyuria Asymptomatic bacteriuria treated
Different antibiotics were compared
Additional single dose group
Allocation concealment A – Adequate
Study Hovelius 1985
Methods Randomisation: sealed envelopes with treatment protocol
Blinding: No
Intention-to-treat: no information
Interim analysis: no information
Excluded: 38/160 - No significant bacteriuria




Data collection: no information
Bacteriuria > 10ˆ4 CFU/ml
Interventions pivmecillinam 400 mg x 3 for 3 days
vs
pivmecillinam 200 mg x 3 for 7 days
(and
nalidixic acid 1 g x 3 for 3 vs 7 days)
Outcomes Bacteriological cure
Adverse effects
Notes 1) Only pivmecillinam groups can be analysed due to treatment regimen change in patients of nalidixic acid
groups
2) Different doses of pivmecillinam were used
3) 2 patients with S.saprophyticus <10ˆ4 CFU included separately
4) Age: 15-45
Allocation concealment B – Unclear
Study Internordic 1988
Methods Randomisation: no information
Blinding: double-blinded
Intention-to-treat: no information
Interim analysis: no information
Excluded for safety analysis: 6/485 patients
Excluded for efficacy analysis: 112/485 (84 - no significant bacteriuria; 3 - lost to follow-up; 8 - treatment
less than 13 doses; 17 - others)





Data collection: 11/85 - 6/87
Bacteriuria > 10ˆ5 CFU/ml for Gram-negative and 10ˆ4 for Staphylococcus saprophyticus
Interventions norfloxacin 400 mg x 2 for 3 days
vs
norfloxacin 400 mg x 2 for 7 days
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Allocation concealment B – Unclear
Study Iravani 1983
Methods Randomisation: no information
Blinding: no information
Intention-to-treat: no information
Interim analysis: no information
Excluded: 12/158 (reasons not mentioned)
Follow-up: 1, 2 and 4 weeks after treatment
Participants USA
158 women college students
Data collection: no information
Bacteriuria > 10ˆ5 CFU/ml
Interventions sulfisoxazole 2 g as first dose followed by
sulfisoxazole 1 g x 4 for 3 days
vs
sulfisoxazole 1g x 4 for 7 days
vs
sulfisoxazole 1 g x 4 for 14 days
vs
sulfisoxazole 1 g x 4 for 21 days
Outcomes Clinical cure
Bacteriological cure
Notes 30 patients had costovertebral tenderness on examination
Age not mentioned (“college coeds”)
Groups of 7, 14 and 21 days will be analysed together (“multi-days”)
Allocation concealment B – Unclear
Study Iravani 1999
Methods Randomisation: opaque gelatin capsules with medication or placebo
Blinding: double blinded
Intention-to-treat: yes
Interim analysis: no information
Excluded: 192/713 (128 - negative cultures; 28 - cultures not obtained; 14 - entry criteria violations; 12 -
inadequate duration of treatment; 3 - insufficient pretreatment colony counts; 3 - administration of con-
cominant antibiotics; 2 - noncompliance; 1 - no follow-up; 1 - resistant organism)




Data collection : no information
Bacteriuria > 10ˆ3 CFU/ml
Interventions ciprofloxacin 100 mg x 2 for 3 days
vs
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Characteristics of included studies (Continued )
TMP-SMX 160/800 mg x 2 or




Notes Different antibiotics were compared
Multicenter trial
Age: 18-85
Bacteriuria > 10ˆ3 CFU/ml
Two groups of 7-days treatment will be analysed together
Allocation concealment A – Adequate
Study Marsh 1980
Methods Randomisation: randomised list
Blinding: no information
Intention-to-treat: no information
Interim analysis: no information
Excluded for clinical efficacy: 16/141 (12 - lost to follow-up; 3 - stopped treatment due to side effects; 1 -
admitted to hospital due to gastritis)
Excluded for bacteriological efficacy analysis: 75/141 (no significant bacteriuria)




Data collection: no information
Bacteriuria > 10ˆ5 CFU/ml
Interventions pivmecillinam (dose not mentioned) for 3 days
vs




Notes Results of clinical cure are presented in the form of symptom score (mean and range) - cannot be analysed
here
Doses of antibiotics not mentioned
Allocation concealment B – Unclear
Study Menday 2000
Methods Randomisation: no information
Blinding: double-blind (double-dummy technique)
Excluded for efficacy analysis: 224/440 (129 - <10ˆ5 CFU/ml of bacterial pathogen; 37 - inadequate urinary
cultures; 54 - bacteria in vitro susceptibility not confirmed; 3 - non-compliance or concominant antibiotic
use; 2 - violated protocol inclusion criteria)
Follow-up: day 10 (+/-2) and day 14 (+/-2) from the beginning of treatment
Participants UK
440 patients
Women: 212 of 216 patients included in efficacy analysis
Age: 18-87 years
Bacteriuria > 10ˆ5 CFU/ml
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Characteristics of included studies (Continued )
Interventions pivmecillinam 200 mg x 3 for 3 days
vs




Notes Different antibiotics doses were compared
Age: 18-87 years
4 of 216 patients included in efficacy analysis were men
Results of clinical cure and improvement are presented together (it‘s impossible to separate between them)
Allocation concealment B – Unclear
Study Neringer 1992
Methods Randomisation: computer-generated randomisation schedule
Blinding: double-dummy method
Intention-to-treat: no information
Interim analysis: no information
Excluded for efficacy analysis: 116/703 (no significant bacteriuria)




Data collection : 8/88 - 1/90
Bacteriuria > 10ˆ4 CFU/ml
Interventions lomefloxacin 400 mg x 1 for 3 days
vs
lomefloxacin 400 mg x 1 for 7 days
vs




Notes One additional group of another antibiotic was included as a 7-day treatment (norfloxacin)
Only two groups (lomefloxacin 400 mg x 1 for 3 vs 7 days) will be analysed here
Allocation concealment A – Adequate
Study Piipo 1990
Methods Randomisation: no information
Blinding: double-blind
Intention-to-treat: no information
Interim analysis: no information
Excluded for efficacy analysis: 73/400 (60 - no significant bacteriuria; 4 - no posttreatment cultures; 4 -
change to other antibiotics; 4 - patients did not take drugs as prescribed; 1 - lost for follow-up)
Follow-up: 3 to 13 days posttreatment and accumulated efficacy (worst result 3 days posttreatment to day




Data collection : no information
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Characteristics of included studies (Continued )
Bacteriuria > 10ˆ5 CFU/ml (10ˆ4 for Staphylococcus saprophyticus)
Interventions norfloxacin 400 mg x 2 for 3 days
vs




Notes Age: 18-80 (results for accumulated long-term efficacy showed for women 18 to 65 years old separately)
Allocation concealment A – Adequate
Study Pitkajarvi 1990




Excluded for clinical and bacteriologicl effect: 46/345 (no growth in th urine cultures) - 23 in both groups




Data collection: no information
Bacteriuria > 10ˆ5 CFU/ml (10ˆ4 for Staphylococcus saprophyticus)
Interventions pivmecillinam 400 mg x 3 for 3 days
vs




Notes Different antibiotics doses were compared
Allocation concealment B – Unclear
Study Rapoport 1981




Excluded: all the cases without significant bacteriuria; 16 of 91 with bacteriuria (lost at follow-up)
Follow-up: 10 to 14 days after treatment
Participants UK
187 patients
Women: 69 of 75 included in analysis
Mean age: 45(14-78)
Data collection: 3/79 - 10/79
Bacteriuria > 10ˆ5 CFU/ml
Interventions TMP-SMX 2 tabs x 1 for 3 days
vs
different drugs* for 7 days
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Characteristics of included studies (Continued )




Notes Age: 14-78 years
Different antibiotics were compared
No outcomes in subgroups of antibiotics in the 7-days group
6 of 75 included in the analysis are males
Allocation concealment B – Unclear
Study Richards 1984
Methods Randomisation: numbered sealed envelopes (opaque not mentioned)
Blinding: Single blinded (investigator)
Intention-to-treat: no information
Interim analysis: no information
Excluded - 8 of 183 (3 - not completed the course due to side effects; 3 - lost to follow-up; 1 - age > 55; 1 -
change in treatment due to worsening symptoms)




Data collection: no information
Bacteriuria > 10ˆ5 CFU/ml
Interventions pivmecillinam 400 mg x 2 for 3 days
vs





Allocation concealment A – Adequate
Study Sandberg 1985
Methods Randomisation: randomisation tables, sealed opaque envelopes containing the allocation number
Blinding: none (open)
Intention-to-treat: no information
Interim analysis: yes (Henning 1982)
Excluded : 80/310 (39 - non-significant bacteriuria; 11 - unknown urine test results; 10 - resistant bacteria;
13 - sensitivity testing for antibiotic not performed; 4 - lost to follow-up; 1 - male; 2 - known anomalies of
urinary tract)
Follow-up: 1 week and 5 weeks after the end of treatment
Participants Sweden
310 non-pregnant women
Age: 16-76 (mean = 35.7)
Data collection : 9/81 - 12/82
Bacteriuria > 10ˆ5 CFU/ml (10ˆ4 for Staphylococcus saprophyticus)
Interventions cefadroxil 1 g x 1 for 3 days
vs
cefadroxil 1 g x 1 for 7 days
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Characteristics of included studies (Continued )
vs
amoxycillin 375 mg x 3 for 7 days
Outcomes Both clinical and bacteriological cure
Adverse effects
Notes Different antibiotics were compared
Two groups of 7-days treatment with different antibiotics were compared with one 3-days group
Only two groups (cefadroxil 1 g x 1 for 3 vs 7 days) will be analysed here
Interim analysis= Henning1982
Allocation concealment A – Adequate
Study Stein 1987
Methods Randomisation: a preassigned random - number code
Blinding: none
Intention-to-treat: yes
Interim analysis: no information
Excluded for efficacy analysis: No significant bacteriuria; Not available for follow-up
Follow-up: 5 to 9 days , 4 to 6 weeks
Participants USA
209 patients
(192 of 209 - women)
Age: 17-85
Data collection: no information
Bacteriuria > 10ˆ5 CFU/ml
Interventions norfloxacin 400 mg x 2 for 3 days
vs





Different antibiotics were compared
17 of 209 patients - males
Allocation concealment B – Unclear
Study Stein 1992
Methods Randomisation: a preassigned random - number code
Blinding: double-blind
Intention-to-treat: no information
Interim analysis: no information
Excluded for efficacy evaluation: 184/404 (most common reason - lack of pretherapy urinary pathogen)
No drop-outs to safety analysis
Follow-up: 5 to 9 days after completion of therapy
Participants USA
404 non-pregnant women
Age : > 18 mean = 44 ; 81/404 - age 65 or more
Data collection: no information
Bacteriuria > 10ˆ4 CFU/ml
Interventions temafloxacin 400 mg x 1 for 3 days
vs
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Characteristics of included studies (Continued )




Notes 81/404 - age 65 or more
Different antibiotics were compared
Allocation concealment B – Unclear
Study Trienekens 1989
Methods Randomisation: no information
Blinding: double dummy technique, placebo tablets identical to active drug
Intention-to-treat: no information
Interim analysis: no information




Data collection : 1/88 - 4/89
Bacteriuria > 10ˆ5 CFU/ml
Interventions TMP-SMX 960 mg x 2 for 3 days
vs





Allocation concealment B – Unclear
Study Trienekens 1993
Methods Randomisation: the code was supplied by pharmaceutic company and was not known to the investigators,
it was kept in the sealed envelopes that was broken 6 weeks after the last patient was included
Blinding: double dummy technique, placebo tablets identical to active drug
Intention-to-treat: no information
Interim analysis: no information
Excluded: 11/395 (not returned for follow-up)




Data collection: 4/89 - 10/90
Bacteriuria > 10ˆ5 CFU/ml
Interventions norfloxacin 400 mg x 2 for 3 days
vs
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Characteristics of included studies (Continued )
Allocation concealment A – Adequate
Study Tsugawa 1999
Methods Randomisation: no information
Blinding: double-blind
Intention-to-treat: no information
Interim analysis: no information
Excluded for efficacy analysis: 28/99 (14 - no significant bacteriuria; 1 - withdrawal of informed consent;
2 - urinary tract infection within 4 weeks before treatment; 2 - lost for follow-up; 1 - fungi in urine before
therapy; 3 - shortage of dosage; 1 - prohibited medication; 1 - anamnesis of epilepsy; 1 - 71 years or older; 1
- out of target disease)




Bacteriuria > 10ˆ4 CFU/ml
Interventions gatifloxacin 100 mg x 2 for 3 days
vs





Allocation concealment B – Unclear
Study Winwick 1981
Methods Randomisation: no information
Blinding: no information
Intention-to-treat: no information
Interim analysis: no information
Excluded: 23/81 (“not fulfilled the stipulated criteria for entry”)
Follow-up: 14 days after treatment start
Participants UK
81 non-pregnant women
Age : 18-65 (mean = 34)
Data collection: no information
Bacteriuria: no information
Interventions nalidixic acid + sodium citrate x 3 for 3 days
vs
ampicillin 500 mg x 3 for 7 days
Outcomes Bacteriological cure
Adverse effects
Notes Exact dosage of antibiotic in the 3-day group not mentioned (probably - 660 mg + 3.75 g)
Different antibiotics were compared
Allocation concealment B – Unclear
TMP = trimethoprim
SMX = sulfamethoxazole
CFU = colony-forming units
28Duration of antibacterial treatment for uncomplicated urinary tract infection in women (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Characteristics of excluded studies
Study Reason for exclusion
Bailey 1983 New Zealand
Randomised controlled study
Compares 2 treatment regimens 5 days duration both
Bargelloni 1972 Italy
Not randomised controlled study
Phase III trial
Blomer 1986 West Germany
Not randomised controlled study








Compares 2 treatment regimens both of 7 days duration (does not include a 3-day regimen)
Furusawa 1994 Japan




Compares single dose and three-days regimens of ciprofloxacin
Hill 1985 UK
Randomised controlled study
Compares 2 treatment regimens 10 days duration both (does not include a 3-day regimen)
Hoigne 1977 Switzerland
Clinical controlled study
Compares treatment for 2 weeks and for 4 weeks
Hooton 1989 USA
Review of two randomised controlled studies :
1) comparing 2 treatment regimens of 3 days both
2) comparing 2 treatment regimens of 7 days both
Iravani 1991 USA
Review of 3 different studies (only one of them - randomised controlled study and included separately)
Iravani 1995 USA
Review of 3 separate studies
Ishihara 1998 Japan
RCT
Results - only clinical improvement and not cure
Little 1979 New Zealand
Randomised controlled study
Compares several treatment regimens all of wich were 5 to 7 days long (does not include a 3-day regimen)
Liudvig 1996 Germany
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Characteristics of excluded studies (Continued )
Not randomised controlled study
Loran 1997 Russia
Not randomised controlled study (case-control study)
Martin 1983 UK
Randomised controlled study
Compares 2 treatment regimens both of 7 days duration (does not include a 3-day regimen)
McCarthy 1972 USA
Randomised controlled study
Compares 2 treatment regimens10 days duration both
Pelta 1985 UK
Randomised controlled study
Compares 2 treatment regimens 7 days duration both (does not include a 3-day regimen)
Raz 1996 Israel
Randomised controlled study
Only postmenopausal women (mean age = 66 +\- 20 years)
Schultz 1984 USA
Randomised controlled study
Compares single-dose with 10-days antibiotic regimens (does not include a 3-day regimen)
Vogel 1984 UK
A summary of few studies comparing different regimens of 3-days therapy and 7-days therapy separately (neither
comparing 3-days treatment to 7-days)
Zorbas 1995 Greece
Randomised controlled study
Duration of all treatment regimens - 12 weeks (does not include a 3-day regimen)
Only elderly patients (mean age = 82.8 years)
A D D I T I O N A L T A B L E S
Table 01. Electronic search strategies
Database searched Terms used
CENTRAL #1) URINARY TRACT INFECTIONS
#2) (urinary next tract next infection*)
#3) uti and utis
#4) bacteriuria*
#5) pyuria*







#13) (nalidixic next acid)
#14) (oxolinic next acid)
#15) fluoroquinolone*
#16) ciprofloxacin
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Table 01. Electronic search strategies (Continued )






#22) (#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21)
#23) (#6 and #22)
MEDLINE 1. exp Urinary Tract Infections/























25. 7 and 24
26. randomized controlled trial.pt.
27. controlled clinical trial.pt.
28. randomized controlled trials/
29. random allocation/
30. double blind method/
31. single blind method/
32. or/26-31
33. animal/ not (animal/ and human/)
34. 32 not 33
35. clinical trial.pt.
36. exp clinical trials/
37. (clinic$ adj25 trial$).ti,ab.
38. cross-over studies/
39. (crossover or cross-over or cross over).tw.
40. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
41. placebos/
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46. 45 not 33
47. 34 or 46
48. 25 and 47
A N A L Y S E S





participants Statistical method Effect size
01 Short-term symptomatic
failure (2-15 days from end of
treatment)
24 5165 Relative Risk (Random) 95% CI 1.06 [0.88, 1.28]
02 Short-term symptomatic failure
- ITT (2-15 days from end of
treatment)
17 5029 Relative Risk (Random) 95% CI 0.98 [0.88, 1.10]
03 Long-term symptomatic failure
(4-10 weeks from end of
treatment)
10 3141 Relative Risk (Random) 95% CI 1.09 [0.94, 1.27]
04 Long-term symptomatic failure
- ITT (4-10 weeks from end of
treatment)
10 3910 Relative Risk (Random) 95% CI 1.07 [0.99, 1.16]
05 Short-term bacteriologic
failure (2-15 days from end of
treatment)
31 5368 Relative Risk (Random) 95% CI 1.19 [0.98, 1.44]
06 Short-term bacteriological
failure by antiboitic class (same
drug) (2-15 days from end of
treatment)
18 3146 Relative Risk (Random) 95% CI 1.37 [1.07, 1.74]
07 Short-term bacteriological
failure - ITT (2-15 days from
end of treatment)
20 4163 Relative Risk (Random) 95% CI 0.92 [0.80, 1.06]
08 Long-term bacteriological
failure (4-10 weeks from end of
treatment)
18 3715 Relative Risk (Random) 95% CI 1.31 [1.08, 1.60]
09 Long-term bacteriological
failure by antibiotic class (same
drug) (4-10 weeks from end of
treatment)
13 2502 Relative Risk (Random) 95% CI 1.43 [1.19, 1.73]
10 Long-term bacteriological
failure - ITT (4-10 weeks from
end of treatment)
13 2943 Relative Risk (Random) 95% CI 1.19 [1.06, 1.35]
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11 Long-term bacteriological
failure - ITT by antibiotic class
(same drug) (4-10 weeks from
end of treatment)
10 2127 Relative Risk (Random) 95% CI 1.26 [1.08, 1.47]
12 Patients with any adverse effects
during treatment
29 7617 Relative Risk (Random) 95% CI 0.83 [0.74, 0.93]
13 Patients developed
pyelonephritis
5 582 Relative Risk (Random) 95% CI 3.04 [0.32, 28.93]
14 Adverse effects requiring
therapy discontinuation
24 6177 Relative Risk (Random) 95% CI 0.51 [0.28, 0.91]
15 Gastrointestinal adverse effects 24 6973 Relative Risk (Random) 95% CI 0.81 [0.67, 0.97]
16 Skin adverse effects 21 6582 Relative Risk (Random) 95% CI 0.62 [0.36, 1.06]
17 CNS adverse effects 21 5748 Relative Risk (Random) 95% CI 0.83 [0.65, 1.06]
18 Vaginal discharge as an adverse
effect of therapy
18 5127 Relative Risk (Random) 95% CI 0.73 [0.49, 1.10]
19 Other adverse effects 19 5250 Relative Risk (Random) 95% CI 0.98 [0.72, 1.32]
20 Patients with any adverse effects
during treatment by antibiotic
class (same drug)
17 3852 Relative Risk (Random) 95% CI 0.76 [0.63, 0.92]
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Infective Agents, Urinary [∗therapeutic use]; Randomized Controlled Trials; Urinary Tract Infections [∗drug therapy]
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G R A P H S A N D O T H E R T A B L E S
Figure 01. Funnel plot - symptomatic failure
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Figure 02. Funnel plot - bacteriologic failure
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Analysis 01.01. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 01 Short-term
symptomatic failure (2-15 days from end of treatment)
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 01 Short-term symptomatic failure (2-15 days from end of treatment)
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
Garcia 2002 5/60 2/58 1.3 2.42 [ 0.49, 11.97 ]
Gossius 1984 9/91 6/95 3.1 1.57 [ 0.58, 4.22 ]
Gossius 1985 4/35 3/37 1.6 1.41 [ 0.34, 5.85 ]
Greenberg 1986 7/22 4/23 2.6 1.83 [ 0.62, 5.39 ]
Hovelius 1985 5/27 4/33 2.1 1.53 [ 0.45, 5.14 ]
Internordic 1988 38/193 27/180 10.7 1.31 [ 0.84, 2.06 ]
Iravani 1983 1/44 2/102 0.6 1.16 [ 0.11, 12.45 ]
Neringer 1992 31/196 26/196 9.7 1.19 [ 0.74, 1.93 ]
Pitkajarvi 1990 24/151 14/148 6.8 1.68 [ 0.90, 3.12 ]
Richards 1984 30/91 32/84 12.3 0.87 [ 0.58, 1.29 ]
Sandberg 1985 16/82 10/72 5.3 1.40 [ 0.68, 2.90 ]
Trienekens 1989 11/121 13/121 4.8 0.85 [ 0.39, 1.81 ]
Trienekens 1993 9/175 18/173 4.7 0.49 [ 0.23, 1.07 ]
Tsugawa 1999 3/34 1/34 0.7 3.00 [ 0.33, 27.42 ]
Subtotal (95% CI) 1322 1356 66.2 1.15 [ 0.95, 1.39 ]
Total events: 193 (Three days), 162 (5-10 days)
Test for heterogeneity chi-square=12.18 df=13 p=0.51 I² =0.0%
Test for overall effect z=1.41 p=0.2
02 Different antibiotic therapy in each group
Bitsch 1985 5/95 11/98 2.9 0.47 [ 0.17, 1.30 ]
Butler 1983 9/31 5/30 3.2 1.74 [ 0.66, 4.60 ]
Cox 1992 5/75 9/66 2.8 0.49 [ 0.17, 1.39 ]
Figueroa 1999 1/20 0/20 0.3 3.00 [ 0.13, 69.52 ]
Guibert 1997 11/177 19/163 5.4 0.53 [ 0.26, 1.09 ]
Henry 1999 29/374 31/369 9.6 0.92 [ 0.57, 1.50 ]
Iravani 1999 8/168 22/351 4.6 0.76 [ 0.35, 1.67 ]
Rapoport 1981 4/41 3/34 1.6 1.11 [ 0.27, 4.60 ]
0.001 0.01 0.1 1 10 100 1000
Favours three days Favours 5-10 days (Continued . . . )
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(. . . Continued)
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Stein 1987 3/74 0/81 0.4 7.65 [ 0.40, 145.73 ]
Stein 1992 12/115 5/105 3.0 2.19 [ 0.80, 6.01 ]
Subtotal (95% CI) 1170 1317 33.8 0.90 [ 0.62, 1.29 ]
Total events: 87 (Three days), 105 (5-10 days)
Test for heterogeneity chi-square=12.57 df=9 p=0.18 I² =28.4%
Test for overall effect z=0.59 p=0.6
Total (95% CI) 2492 2673 100.0 1.06 [ 0.88, 1.28 ]
Total events: 280 (Three days), 267 (5-10 days)
Test for heterogeneity chi-square=27.14 df=23 p=0.25 I² =15.3%
Test for overall effect z=0.65 p=0.5
0.001 0.01 0.1 1 10 100 1000
Favours three days Favours 5-10 days
Analysis 01.02. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 02 Short-term
symptomatic failure - ITT (2-15 days from end of treatment)
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 02 Short-term symptomatic failure - ITT (2-15 days from end of treatment)
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
Greenberg 1986 10/25 7/26 2.0 1.49 [ 0.67, 3.29 ]
Internordic 1988 50/205 43/196 8.6 1.11 [ 0.78, 1.59 ]
Iravani 1983 6/49 9/109 1.3 1.48 [ 0.56, 3.94 ]
Neringer 1992 31/196 26/196 5.1 1.19 [ 0.74, 1.93 ]
Pitkajarvi 1990 24/151 14/148 3.2 1.68 [ 0.90, 3.12 ]
Richards 1984 33/94 37/89 8.1 0.84 [ 0.58, 1.22 ]
Sandberg 1985 26/92 24/86 5.3 1.01 [ 0.63, 1.62 ]
Trienekens 1989 51/161 58/166 11.0 0.91 [ 0.67, 1.23 ]
Trienekens 1993 33/199 41/196 6.7 0.79 [ 0.52, 1.20 ]
Tsugawa 1999 13/44 8/41 2.1 1.51 [ 0.70, 3.27 ]
Subtotal (95% CI) 1216 1253 53.5 1.02 [ 0.89, 1.18 ]
Total events: 277 (Three days), 267 (5-10 days)
Test for heterogeneity chi-square=8.59 df=9 p=0.48 I² =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours three days Favours 5-10 days (Continued . . . )
38Duration of antibacterial treatment for uncomplicated urinary tract infection in women (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
(. . . Continued)
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Test for overall effect z=0.31 p=0.8
02 Different antibiotic therapy in each group
Cox 1992 11/81 23/82 2.9 0.48 [ 0.25, 0.93 ]
Figueroa 1999 1/20 0/20 0.1 3.00 [ 0.13, 69.52 ]
Guibert 1997 46/212 55/209 9.3 0.82 [ 0.59, 1.16 ]
Henry 1999 49/394 48/386 8.0 1.00 [ 0.69, 1.45 ]
Iravani 1999 79/239 145/474 17.3 1.08 [ 0.86, 1.35 ]
Stein 1987 3/74 0/81 0.2 7.65 [ 0.40, 145.73 ]
Stein 1992 39/142 47/146 8.6 0.85 [ 0.60, 1.22 ]
Subtotal (95% CI) 1162 1398 46.5 0.91 [ 0.74, 1.12 ]
Total events: 228 (Three days), 318 (5-10 days)
Test for heterogeneity chi-square=8.90 df=6 p=0.18 I² =32.6%
Test for overall effect z=0.89 p=0.4
Total (95% CI) 2378 2651 100.0 0.98 [ 0.88, 1.10 ]
Total events: 505 (Three days), 585 (5-10 days)
Test for heterogeneity chi-square=18.08 df=16 p=0.32 I² =11.5%
Test for overall effect z=0.30 p=0.8
0.001 0.01 0.1 1 10 100 1000
Favours three days Favours 5-10 days
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Analysis 01.03. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 03 Long-term
symptomatic failure (4-10 weeks from end of treatment)
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 03 Long-term symptomatic failure (4-10 weeks from end of treatment)
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
Internordic 1988 39/193 21/180 8.4 1.73 [ 1.06, 2.83 ]
Neringer 1992 55/196 53/196 16.7 1.04 [ 0.75, 1.43 ]
Piipo 1990 20/164 15/163 5.3 1.33 [ 0.70, 2.50 ]
Pitkajarvi 1990 41/145 28/133 11.0 1.34 [ 0.88, 2.04 ]
Sandberg 1985 35/77 28/65 13.4 1.06 [ 0.73, 1.53 ]
Trienekens 1989 19/116 17/123 5.8 1.19 [ 0.65, 2.17 ]
Trienekens 1993 19/150 28/155 7.1 0.70 [ 0.41, 1.20 ]
Tsugawa 1999 5/33 1/32 0.5 4.85 [ 0.60, 39.25 ]
Subtotal (95% CI) 1074 1047 68.2 1.16 [ 0.95, 1.42 ]
Total events: 233 (Three days), 191 (5-10 days)
Test for heterogeneity chi-square=9.13 df=7 p=0.24 I² =23.3%
Test for overall effect z=1.48 p=0.1
02 Different antibiotic therapy in each group
Henry 1999 75/261 82/280 22.1 0.98 [ 0.75, 1.28 ]
Iravani 1999 23/155 52/324 9.7 0.92 [ 0.59, 1.45 ]
Subtotal (95% CI) 416 604 31.8 0.97 [ 0.77, 1.21 ]
Total events: 98 (Three days), 134 (5-10 days)
Test for heterogeneity chi-square=0.05 df=1 p=0.82 I² =0.0%
Test for overall effect z=0.29 p=0.8
Total (95% CI) 1490 1651 100.0 1.09 [ 0.94, 1.27 ]
Total events: 331 (Three days), 325 (5-10 days)
Test for heterogeneity chi-square=10.62 df=9 p=0.30 I² =15.3%
Test for overall effect z=1.13 p=0.3
0.01 0.1 1 10 100
Favours three days Favours 5-10 days
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Analysis 01.04. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 04 Long-term
symptomatic failure - ITT (4-10 weeks from end of treatment)
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 04 Long-term symptomatic failure - ITT (4-10 weeks from end of treatment)
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
Internordic 1988 51/205 37/196 4.5 1.32 [ 0.91, 1.92 ]
Neringer 1992 55/196 53/196 6.2 1.04 [ 0.75, 1.43 ]
Piipo 1990 26/170 22/170 2.3 1.18 [ 0.70, 2.00 ]
Pitkajarvi 1990 47/151 43/148 5.3 1.07 [ 0.76, 1.51 ]
Sandberg 1985 50/92 49/86 9.3 0.95 [ 0.73, 1.24 ]
Trienekens 1989 64/161 60/166 8.3 1.10 [ 0.83, 1.45 ]
Trienekens 1993 68/199 69/196 8.7 0.97 [ 0.74, 1.27 ]
Tsugawa 1999 17/44 10/41 1.5 1.58 [ 0.82, 3.05 ]
Subtotal (95% CI) 1218 1199 46.1 1.07 [ 0.95, 1.20 ]
Total events: 378 (Three days), 343 (5-10 days)
Test for heterogeneity chi-square=4.06 df=7 p=0.77 I² =0.0%
Test for overall effect z=1.09 p=0.3
02 Different antibiotic therapy in each group
Henry 1999 208/394 188/386 33.2 1.08 [ 0.94, 1.25 ]
Iravani 1999 107/239 202/474 20.7 1.05 [ 0.88, 1.25 ]
Subtotal (95% CI) 633 860 53.9 1.07 [ 0.96, 1.19 ]
Total events: 315 (Three days), 390 (5-10 days)
Test for heterogeneity chi-square=0.08 df=1 p=0.78 I² =0.0%
Test for overall effect z=1.24 p=0.2
Total (95% CI) 1851 2059 100.0 1.07 [ 0.99, 1.16 ]
Total events: 693 (Three days), 733 (5-10 days)
Test for heterogeneity chi-square=4.11 df=9 p=0.90 I² =0.0%
Test for overall effect z=1.64 p=0.1
0.2 0.5 1 2 5
Favours three days Favours 5-10 days
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Analysis 01.05. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 05 Short-term
bacteriologic failure (2-15 days from end of treatment)
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 05 Short-term bacteriologic failure (2-15 days from end of treatment)
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
Garcia 2002 7/60 4/58 2.6 1.69 [ 0.52, 5.47 ]
Gordin 1987a 1/32 1/30 0.5 0.94 [ 0.06, 14.33 ]
Gordin 1987b 6/36 7/34 3.8 0.81 [ 0.30, 2.17 ]
Gossius 1984 6/91 3/95 2.0 2.09 [ 0.54, 8.10 ]
Gossius 1985 2/35 1/37 0.7 2.11 [ 0.20, 22.29 ]
Greenberg 1986 7/22 5/24 3.7 1.53 [ 0.57, 4.12 ]
Hansen 1981 7/102 15/119 4.9 0.54 [ 0.23, 1.28 ]
Hovelius 1985 5/27 4/33 2.5 1.53 [ 0.45, 5.14 ]
Internordic 1988 12/193 11/180 5.8 1.02 [ 0.46, 2.25 ]
Iravani 1983 1/44 2/102 0.6 1.16 [ 0.11, 12.45 ]
Marsh 1980 5/22 5/32 2.9 1.45 [ 0.48, 4.43 ]
Neringer 1992 24/196 14/196 9.2 1.71 [ 0.91, 3.21 ]
Piipo 1990 4/163 4/162 1.9 0.99 [ 0.25, 3.91 ]
Pitkajarvi 1990 13/151 9/148 5.4 1.42 [ 0.62, 3.21 ]
Richards 1984 4/22 3/26 1.9 1.58 [ 0.39, 6.30 ]
Trienekens 1989 19/132 10/136 6.9 1.96 [ 0.95, 4.05 ]
Trienekens 1993 14/169 8/169 5.1 1.75 [ 0.75, 4.06 ]
Tsugawa 1999 1/34 0/34 0.4 3.00 [ 0.13, 71.15 ]
Subtotal (95% CI) 1531 1615 60.8 1.37 [ 1.07, 1.74 ]
Total events: 138 (Three days), 106 (5-10 days)
Test for heterogeneity chi-square=9.13 df=17 p=0.94 I² =0.0%
Test for overall effect z=2.50 p=0.01
02 Different antibiotic therapy in each group
Basista 1991 4/29 5/25 2.5 0.69 [ 0.21, 2.29 ]
Bitsch 1985 5/95 11/98 3.5 0.47 [ 0.17, 1.30 ]
Butler 1983 3/27 1/27 0.8 3.00 [ 0.33, 27.06 ]
Cox 1992 2/75 2/68 1.0 0.91 [ 0.13, 6.26 ]
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Figueroa 1999 1/20 2/20 0.7 0.50 [ 0.05, 5.08 ]
Henry 1999 15/203 7/203 4.7 2.14 [ 0.89, 5.14 ]
Hooton 1991 4/48 2/44 1.3 1.83 [ 0.35, 9.52 ]
Iravani 1999 20/168 37/351 13.9 1.13 [ 0.68, 1.88 ]
Menday 2000 11/107 20/109 7.7 0.56 [ 0.28, 1.11 ]
Rapoport 1981 2/41 2/34 1.0 0.83 [ 0.12, 5.58 ]
Stein 1987 3/74 0/81 0.4 7.65 [ 0.40, 145.73 ]
Stein 1992 3/115 4/105 1.7 0.68 [ 0.16, 2.99 ]
x Winwick 1981 0/29 0/26 0.0 Not estimable
Subtotal (95% CI) 1031 1191 39.2 0.96 [ 0.68, 1.35 ]
Total events: 73 (Three days), 93 (5-10 days)
Test for heterogeneity chi-square=12.28 df=11 p=0.34 I² =10.4%
Test for overall effect z=0.26 p=0.8
Total (95% CI) 2562 2806 100.0 1.19 [ 0.98, 1.44 ]
Total events: 211 (Three days), 199 (5-10 days)
Test for heterogeneity chi-square=24.54 df=29 p=0.70 I² =0.0%
Test for overall effect z=1.78 p=0.08
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Analysis 01.06. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 06 Short-term
bacteriological failure by antiboitic class (same drug) (2-15 days from end of treatment)
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 06 Short-term bacteriological failure by antiboitic class (same drug) (2-15 days from end of treatment)
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Quinolones
Garcia 2002 7/60 4/58 4.3 1.69 [ 0.52, 5.47 ]
Internordic 1988 12/193 11/180 9.5 1.02 [ 0.46, 2.25 ]
Neringer 1992 24/196 14/196 15.1 1.71 [ 0.91, 3.21 ]
Piipo 1990 4/163 4/162 3.2 0.99 [ 0.25, 3.91 ]
Trienekens 1993 14/169 8/169 8.4 1.75 [ 0.75, 4.06 ]
Tsugawa 1999 1/34 0/34 0.6 3.00 [ 0.13, 71.15 ]
Subtotal (95% CI) 815 799 41.2 1.47 [ 1.01, 2.16 ]
Total events: 62 (Three days), 41 (5-10 days)
Test for heterogeneity chi-square=1.79 df=5 p=0.88 I² =0.0%
Test for overall effect z=1.99 p=0.05
02 Beta-lactams
Gordin 1987b 6/36 7/34 6.2 0.81 [ 0.30, 2.17 ]
Greenberg 1986 7/22 5/24 6.1 1.53 [ 0.57, 4.12 ]
Hansen 1981 7/102 15/119 8.1 0.54 [ 0.23, 1.28 ]
Hovelius 1985 5/27 4/33 4.1 1.53 [ 0.45, 5.14 ]
Marsh 1980 5/22 5/32 4.8 1.45 [ 0.48, 4.43 ]
Pitkajarvi 1990 13/151 9/148 8.9 1.42 [ 0.62, 3.21 ]
Richards 1984 4/22 3/26 3.1 1.58 [ 0.39, 6.30 ]
Subtotal (95% CI) 382 416 41.3 1.11 [ 0.76, 1.63 ]
Total events: 47 (Three days), 48 (5-10 days)
Test for heterogeneity chi-square=4.54 df=6 p=0.60 I² =0.0%
Test for overall effect z=0.55 p=0.6
03 TMP/sulfonamides
Gordin 1987a 1/32 1/30 0.8 0.94 [ 0.06, 14.33 ]
Gossius 1984 6/91 3/95 3.3 2.09 [ 0.54, 8.10 ]
Gossius 1985 2/35 1/37 1.1 2.11 [ 0.20, 22.29 ]
Iravani 1983 1/44 2/102 1.1 1.16 [ 0.11, 12.45 ]
Trienekens 1989 19/132 10/136 11.3 1.96 [ 0.95, 4.05 ]
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Subtotal (95% CI) 334 400 17.5 1.86 [ 1.04, 3.34 ]
Total events: 29 (Three days), 17 (5-10 days)
Test for heterogeneity chi-square=0.45 df=4 p=0.98 I² =0.0%
Test for overall effect z=2.09 p=0.04
Total (95% CI) 1531 1615 100.0 1.37 [ 1.07, 1.74 ]
Total events: 138 (Three days), 106 (5-10 days)
Test for heterogeneity chi-square=9.13 df=17 p=0.94 I² =0.0%
Test for overall effect z=2.50 p=0.01
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Analysis 01.07. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 07 Short-term
bacteriological failure - ITT (2-15 days from end of treatment)
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 07 Short-term bacteriological failure - ITT (2-15 days from end of treatment)
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
Gordin 1987a 2/33 6/35 0.8 0.35 [ 0.08, 1.63 ]
Gordin 1987b 6/36 8/35 2.1 0.73 [ 0.28, 1.89 ]
Greenberg 1986 10/25 7/26 2.9 1.49 [ 0.67, 3.29 ]
Hansen 1981 7/102 15/119 2.6 0.54 [ 0.23, 1.28 ]
Hovelius 1985 5/27 4/33 1.3 1.53 [ 0.45, 5.14 ]
Internordic 1988 24/205 27/196 6.5 0.85 [ 0.51, 1.42 ]
Iravani 1983 6/49 9/109 2.0 1.48 [ 0.56, 3.94 ]
Neringer 1992 24/196 14/196 4.5 1.71 [ 0.91, 3.21 ]
Piipo 1990 11/170 12/170 3.0 0.92 [ 0.42, 2.02 ]
Pitkajarvi 1990 13/151 9/148 2.8 1.42 [ 0.62, 3.21 ]
Trienekens 1989 48/161 49/166 12.9 1.01 [ 0.72, 1.41 ]
Tsugawa 1999 11/44 7/41 2.6 1.46 [ 0.63, 3.41 ]
Subtotal (95% CI) 1199 1274 44.0 1.06 [ 0.87, 1.29 ]
Total events: 167 (Three days), 167 (5-10 days)
Test for heterogeneity chi-square=10.61 df=11 p=0.48 I² =0.0%
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Test for overall effect z=0.56 p=0.6
02 Different antibiotic therapy in each group
Basista 1991 12/37 15/35 4.9 0.76 [ 0.41, 1.38 ]
Cox 1992 8/81 16/82 3.0 0.51 [ 0.23, 1.12 ]
Figueroa 1999 1/20 2/20 0.4 0.50 [ 0.05, 5.08 ]
Henry 1999 89/277 92/288 19.7 1.01 [ 0.79, 1.28 ]
Hooton 1991 5/49 5/47 1.4 0.96 [ 0.30, 3.10 ]
Menday 2000 52/148 74/163 16.7 0.77 [ 0.59, 1.02 ]
Stein 1987 3/74 0/81 0.2 7.65 [ 0.40, 145.73 ]
Stein 1992 30/142 45/146 9.8 0.69 [ 0.46, 1.02 ]
Subtotal (95% CI) 828 862 56.0 0.83 [ 0.70, 0.98 ]
Total events: 200 (Three days), 249 (5-10 days)
Test for heterogeneity chi-square=7.58 df=7 p=0.37 I² =7.7%
Test for overall effect z=2.15 p=0.03
Total (95% CI) 2027 2136 100.0 0.92 [ 0.80, 1.06 ]
Total events: 367 (Three days), 416 (5-10 days)
Test for heterogeneity chi-square=21.52 df=19 p=0.31 I² =11.7%
Test for overall effect z=1.17 p=0.2
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Analysis 01.08. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 08 Long-term
bacteriological failure (4-10 weeks from end of treatment)
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 08 Long-term bacteriological failure (4-10 weeks from end of treatment)
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
Gordin 1987a 6/30 2/28 1.5 2.80 [ 0.62, 12.74 ]
Gordin 1987b 11/33 9/33 5.2 1.22 [ 0.58, 2.55 ]
Gossius 1984 12/91 6/93 3.6 2.04 [ 0.80, 5.21 ]
Gossius 1985 5/35 3/37 1.9 1.76 [ 0.45, 6.83 ]
Greenberg 1986 9/18 9/21 5.9 1.17 [ 0.59, 2.29 ]
Internordic 1988 36/193 15/180 7.4 2.24 [ 1.27, 3.95 ]
Iravani 1983 5/44 13/102 3.4 0.89 [ 0.34, 2.35 ]
Neringer 1992 37/196 35/196 10.5 1.06 [ 0.70, 1.61 ]
Piipo 1990 15/129 12/133 5.4 1.29 [ 0.63, 2.65 ]
Pitkajarvi 1990 28/134 15/128 7.3 1.78 [ 1.00, 3.18 ]
Trienekens 1989 31/139 23/151 8.9 1.46 [ 0.90, 2.38 ]
Trienekens 1993 28/152 18/144 7.8 1.47 [ 0.85, 2.55 ]
Tsugawa 1999 2/31 0/31 0.4 5.00 [ 0.25, 100.08 ]
Subtotal (95% CI) 1225 1277 69.0 1.43 [ 1.19, 1.73 ]
Total events: 225 (Three days), 160 (5-10 days)
Test for heterogeneity chi-square=8.65 df=12 p=0.73 I² =0.0%
Test for overall effect z=3.76 p=0.0002
02 Different antibiotic therapy in each group
Bitsch 1985 19/69 21/68 8.2 0.89 [ 0.53, 1.50 ]
Henry 1999 20/203 15/203 6.3 1.33 [ 0.70, 2.53 ]
Hooton 1991 9/49 3/44 2.2 2.69 [ 0.78, 9.32 ]
Iravani 1999 32/150 94/322 12.2 0.73 [ 0.51, 1.04 ]
Stein 1987 7/47 3/58 2.0 2.88 [ 0.79, 10.53 ]
Subtotal (95% CI) 518 695 31.0 1.13 [ 0.73, 1.77 ]
Total events: 87 (Three days), 136 (5-10 days)
Test for heterogeneity chi-square=8.85 df=4 p=0.06 I² =54.8%
Test for overall effect z=0.55 p=0.6
Total (95% CI) 1743 1972 100.0 1.31 [ 1.08, 1.60 ]
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Total events: 312 (Three days), 296 (5-10 days)
Test for heterogeneity chi-square=24.40 df=17 p=0.11 I² =30.3%
Test for overall effect z=2.75 p=0.006
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Analysis 01.09. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 09 Long-term
bacteriological failure by antibiotic class (same drug) (4-10 weeks from end of treatment)
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 09 Long-term bacteriological failure by antibiotic class (same drug) (4-10 weeks from end of treatment)
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Quinolones
Internordic 1988 36/193 15/180 10.9 2.24 [ 1.27, 3.95 ]
Neringer 1992 37/196 35/196 20.0 1.06 [ 0.70, 1.61 ]
Piipo 1990 15/129 12/133 6.7 1.29 [ 0.63, 2.65 ]
Trienekens 1993 28/152 18/144 11.7 1.47 [ 0.85, 2.55 ]
Tsugawa 1999 2/31 0/31 0.4 5.00 [ 0.25, 100.08 ]
Subtotal (95% CI) 701 684 49.7 1.43 [ 1.04, 1.97 ]
Total events: 118 (Three days), 80 (5-10 days)
Test for heterogeneity chi-square=5.18 df=4 p=0.27 I² =22.8%
Test for overall effect z=2.22 p=0.03
02 Beta-lactams
Gordin 1987b 11/33 9/33 6.4 1.22 [ 0.58, 2.55 ]
Greenberg 1986 9/18 9/21 7.6 1.17 [ 0.59, 2.29 ]
Pitkajarvi 1990 28/134 15/128 10.4 1.78 [ 1.00, 3.18 ]
Subtotal (95% CI) 185 182 24.5 1.41 [ 0.97, 2.06 ]
Total events: 48 (Three days), 33 (5-10 days)
Test for heterogeneity chi-square=1.12 df=2 p=0.57 I² =0.0%
Test for overall effect z=1.80 p=0.07
03 TMP/sulfonamides
Gordin 1987a 6/30 2/28 1.5 2.80 [ 0.62, 12.74 ]
Gossius 1984 12/91 6/93 4.0 2.04 [ 0.80, 5.21 ]
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Gossius 1985 5/35 3/37 1.9 1.76 [ 0.45, 6.83 ]
Iravani 1983 5/44 13/102 3.7 0.89 [ 0.34, 2.35 ]
Trienekens 1989 31/139 23/151 14.7 1.46 [ 0.90, 2.38 ]
Subtotal (95% CI) 339 411 25.8 1.51 [ 1.05, 2.18 ]
Total events: 59 (Three days), 47 (5-10 days)
Test for heterogeneity chi-square=2.24 df=4 p=0.69 I² =0.0%
Test for overall effect z=2.20 p=0.03
Total (95% CI) 1225 1277 100.0 1.43 [ 1.19, 1.73 ]
Total events: 225 (Three days), 160 (5-10 days)
Test for heterogeneity chi-square=8.65 df=12 p=0.73 I² =0.0%
Test for overall effect z=3.76 p=0.0002
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Analysis 01.10. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 10 Long-term
bacteriological failure - ITT (4-10 weeks from end of treatment)
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 10 Long-term bacteriological failure - ITT (4-10 weeks from end of treatment)
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
Gordin 1987a 9/33 9/35 2.3 1.06 [ 0.48, 2.34 ]
Gordin 1987b 14/36 11/35 3.6 1.24 [ 0.65, 2.34 ]
Greenberg 1986 16/25 13/26 6.2 1.28 [ 0.79, 2.08 ]
Internordic 1988 48/205 31/196 8.7 1.48 [ 0.99, 2.22 ]
Iravani 1983 10/49 20/109 3.1 1.11 [ 0.56, 2.20 ]
Neringer 1992 37/196 35/196 8.3 1.06 [ 0.70, 1.61 ]
Piipo 1990 21/135 19/140 4.4 1.15 [ 0.65, 2.03 ]
Pitkajarvi 1990 45/151 35/148 10.1 1.26 [ 0.86, 1.84 ]
Trienekens 1989 53/161 38/166 11.4 1.44 [ 1.01, 2.05 ]
Tsugawa 1999 12/44 10/41 2.8 1.12 [ 0.54, 2.30 ]
Subtotal (95% CI) 1035 1092 60.9 1.26 [ 1.08, 1.47 ]
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Total events: 265 (Three days), 221 (5-10 days)
Test for heterogeneity chi-square=2.34 df=9 p=0.98 I² =0.0%
Test for overall effect z=2.93 p=0.003
02 Different antibiotic therapy in each group
Henry 1999 94/277 100/288 27.8 0.98 [ 0.78, 1.23 ]
Hooton 1991 13/49 8/47 2.4 1.56 [ 0.71, 3.42 ]
Stein 1987 34/74 26/81 9.0 1.43 [ 0.96, 2.14 ]
Subtotal (95% CI) 400 416 39.1 1.18 [ 0.87, 1.60 ]
Total events: 141 (Three days), 134 (5-10 days)
Test for heterogeneity chi-square=3.44 df=2 p=0.18 I² =41.9%
Test for overall effect z=1.04 p=0.3
Total (95% CI) 1435 1508 100.0 1.19 [ 1.06, 1.35 ]
Total events: 406 (Three days), 355 (5-10 days)
Test for heterogeneity chi-square=6.98 df=12 p=0.86 I² =0.0%
Test for overall effect z=2.88 p=0.004
0.2 0.5 1 2 5
Favours three days Favours 5-10 days
Analysis 01.11. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 11 Long-term
bacteriological failure - ITT by antibiotic class (same drug) (4-10 weeks from end of treatment)
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 11 Long-term bacteriological failure - ITT by antibiotic class (same drug) (4-10 weeks from end of treatment)
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Quinolones
Internordic 1988 48/205 31/196 14.4 1.48 [ 0.99, 2.22 ]
Neringer 1992 37/196 35/196 13.6 1.06 [ 0.70, 1.61 ]
Piipo 1990 21/135 19/140 7.2 1.15 [ 0.65, 2.03 ]
Tsugawa 1999 12/44 10/41 4.5 1.12 [ 0.54, 2.30 ]
Subtotal (95% CI) 580 573 39.8 1.22 [ 0.95, 1.56 ]
Total events: 118 (Three days), 95 (5-10 days)
Test for heterogeneity chi-square=1.42 df=3 p=0.70 I² =0.0%
Test for overall effect z=1.59 p=0.1
02 Beta-lactams
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Gordin 1987b 14/36 11/35 5.8 1.24 [ 0.65, 2.34 ]
Greenberg 1986 16/25 13/26 10.2 1.28 [ 0.79, 2.08 ]
Pitkajarvi 1990 45/151 35/148 16.5 1.26 [ 0.86, 1.84 ]
Subtotal (95% CI) 212 209 32.5 1.26 [ 0.96, 1.65 ]
Total events: 75 (Three days), 59 (5-10 days)
Test for heterogeneity chi-square=0.01 df=2 p=1.00 I² =0.0%
Test for overall effect z=1.69 p=0.09
03 TMP/sulfonamides
Gordin 1987a 9/33 9/35 3.8 1.06 [ 0.48, 2.34 ]
Iravani 1983 10/49 20/109 5.1 1.11 [ 0.56, 2.20 ]
Trienekens 1989 53/161 38/166 18.8 1.44 [ 1.01, 2.05 ]
Subtotal (95% CI) 243 310 27.7 1.32 [ 0.98, 1.76 ]
Total events: 72 (Three days), 67 (5-10 days)
Test for heterogeneity chi-square=0.76 df=2 p=0.68 I² =0.0%
Test for overall effect z=1.83 p=0.07
Total (95% CI) 1035 1092 100.0 1.26 [ 1.08, 1.47 ]
Total events: 265 (Three days), 221 (5-10 days)
Test for heterogeneity chi-square=2.34 df=9 p=0.98 I² =0.0%
Test for overall effect z=2.93 p=0.003
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Analysis 01.12. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 12 Patients with any
adverse effects during treatment
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 12 Patients with any adverse effects during treatment
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
Gordin 1987a 0/32 5/30 0.2 0.09 [ 0.00, 1.48 ]
Gordin 1987b 2/36 3/34 0.4 0.63 [ 0.11, 3.54 ]
Gossius 1984 12/136 37/132 3.0 0.31 [ 0.17, 0.58 ]
Gossius 1985 4/50 18/64 1.1 0.28 [ 0.10, 0.79 ]
Greenberg 1986 0/26 1/28 0.1 0.36 [ 0.02, 8.42 ]
Hansen 1981 3/102 7/119 0.7 0.50 [ 0.13, 1.88 ]
Hovelius 1985 2/27 1/33 0.2 2.44 [ 0.23, 25.53 ]
Internordic 1988 46/239 58/240 7.7 0.80 [ 0.57, 1.12 ]
Marsh 1980 17/59 22/69 3.8 0.90 [ 0.53, 1.53 ]
Neringer 1992 57/228 73/235 9.5 0.80 [ 0.60, 1.08 ]
Piipo 1990 28/197 22/197 3.9 1.27 [ 0.75, 2.15 ]
Pitkajarvi 1990 21/174 20/171 3.3 1.03 [ 0.58, 1.83 ]
Richards 1984 8/92 15/86 1.8 0.50 [ 0.22, 1.12 ]
Sandberg 1985 10/102 12/100 1.8 0.82 [ 0.37, 1.80 ]
Trienekens 1989 40/161 51/166 7.4 0.81 [ 0.57, 1.15 ]
Trienekens 1993 26/199 29/193 4.4 0.87 [ 0.53, 1.42 ]
Tsugawa 1999 4/45 5/50 0.8 0.89 [ 0.25, 3.11 ]
Subtotal (95% CI) 1905 1947 50.1 0.76 [ 0.63, 0.92 ]
Total events: 280 (Three days), 379 (5-10 days)
Test for heterogeneity chi-square=22.63 df=16 p=0.12 I² =29.3%
Test for overall effect z=2.87 p=0.004
02 Different antibiotic therapy in each group
Basista 1991 5/49 9/45 1.2 0.51 [ 0.18, 1.41 ]
Bitsch 1985 6/158 5/152 0.9 1.15 [ 0.36, 3.70 ]
Cox 1992 14/101 19/99 2.8 0.72 [ 0.38, 1.36 ]
x Figueroa 1999 0/20 0/20 0.0 Not estimable
Guibert 1997 33/212 34/209 5.2 0.96 [ 0.62, 1.48 ]
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Henry 1999 119/394 106/386 13.3 1.10 [ 0.88, 1.37 ]
Hooton 1991 16/49 19/47 3.8 0.81 [ 0.47, 1.37 ]
Iravani 1999 68/239 170/474 12.5 0.79 [ 0.63, 1.00 ]
Menday 2000 13/219 16/221 2.3 0.82 [ 0.40, 1.66 ]
Stein 1987 15/109 15/100 2.6 0.92 [ 0.47, 1.78 ]
Stein 1992 24/197 31/207 4.3 0.81 [ 0.50, 1.34 ]
Winwick 1981 6/30 6/28 1.2 0.93 [ 0.34, 2.56 ]
Subtotal (95% CI) 1777 1988 49.9 0.90 [ 0.80, 1.03 ]
Total events: 319 (Three days), 430 (5-10 days)
Test for heterogeneity chi-square=6.59 df=10 p=0.76 I² =0.0%
Test for overall effect z=1.53 p=0.1
Total (95% CI) 3682 3935 100.0 0.83 [ 0.74, 0.93 ]
Total events: 599 (Three days), 809 (5-10 days)
Test for heterogeneity chi-square=31.55 df=27 p=0.25 I² =14.4%
Test for overall effect z=3.30 p=0.001
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Analysis 01.13. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 13 Patients
developed pyelonephritis
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 13 Patients developed pyelonephritis
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
Gossius 1984 1/91 0/95 49.9 3.13 [ 0.13, 75.87 ]
Gossius 1985 1/68 0/67 50.1 2.96 [ 0.12, 71.31 ]
x Hovelius 1985 0/27 0/33 0.0 Not estimable
Subtotal (95% CI) 186 195 100.0 3.04 [ 0.32, 28.93 ]
Total events: 2 (Three days), 0 (5-10 days)
Test for heterogeneity chi-square=0.00 df=1 p=0.98 I² =0.0%
Test for overall effect z=0.97 p=0.3
02 Different antibiotic therapy in each group
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
x Cox 1992 0/75 0/68 0.0 Not estimable
x Winwick 1981 0/30 0/28 0.0 Not estimable
Subtotal (95% CI) 105 96 0.0 Not estimable
Total events: 0 (Three days), 0 (5-10 days)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 291 291 100.0 3.04 [ 0.32, 28.93 ]
Total events: 2 (Three days), 0 (5-10 days)
Test for heterogeneity chi-square=0.00 df=1 p=0.98 I² =0.0%
Test for overall effect z=0.97 p=0.3
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Analysis 01.14. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 14 Adverse effects
requiring therapy discontinuation
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 14 Adverse effects requiring therapy discontinuation
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
Gordin 1987a 0/32 3/30 3.2 0.13 [ 0.01, 2.49 ]
x Gordin 1987b 0/36 0/34 0.0 Not estimable
Gossius 1984 0/136 20/132 3.4 0.02 [ 0.00, 0.39 ]
Gossius 1985 1/50 9/64 5.4 0.14 [ 0.02, 1.09 ]
x Greenberg 1986 0/26 0/28 0.0 Not estimable
x Hovelius 1985 0/27 0/33 0.0 Not estimable
Internordic 1988 6/239 5/240 9.5 1.21 [ 0.37, 3.90 ]
Marsh 1980 1/59 2/69 4.3 0.58 [ 0.05, 6.29 ]
Neringer 1992 2/228 14/235 7.8 0.15 [ 0.03, 0.64 ]
Piipo 1990 5/197 0/197 3.2 11.00 [ 0.61, 197.60 ]
x Pitkajarvi 1990 0/174 0/171 0.0 Not estimable
Richards 1984 1/92 2/86 4.3 0.47 [ 0.04, 5.06 ]
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Sandberg 1985 0/102 2/100 3.0 0.20 [ 0.01, 4.03 ]
Subtotal (95% CI) 1398 1419 44.0 0.35 [ 0.12, 0.98 ]
Total events: 16 (Three days), 57 (5-10 days)
Test for heterogeneity chi-square=16.56 df=8 p=0.04 I² =51.7%
Test for overall effect z=2.01 p=0.04
02 Different antibiotic therapy in each group
Bitsch 1985 1/158 0/152 2.7 2.89 [ 0.12, 70.32 ]
Butler 1983 0/59 1/51 2.7 0.29 [ 0.01, 6.94 ]
Cox 1992 0/101 3/99 3.1 0.14 [ 0.01, 2.68 ]
x Figueroa 1999 0/20 0/20 0.0 Not estimable
Henry 1999 17/394 10/386 12.2 1.67 [ 0.77, 3.59 ]
Hooton 1991 0/49 1/47 2.8 0.32 [ 0.01, 7.66 ]
Iravani 1999 3/239 18/474 9.3 0.33 [ 0.10, 1.11 ]
Menday 2000 4/219 4/221 8.3 1.01 [ 0.26, 3.98 ]
Stein 1987 2/109 4/100 6.8 0.46 [ 0.09, 2.45 ]
Stein 1992 3/197 5/207 8.1 0.63 [ 0.15, 2.60 ]
x Winwick 1981 0/30 0/28 0.0 Not estimable
Subtotal (95% CI) 1575 1785 56.0 0.78 [ 0.45, 1.34 ]
Total events: 30 (Three days), 46 (5-10 days)
Test for heterogeneity chi-square=8.92 df=8 p=0.35 I² =10.4%
Test for overall effect z=0.91 p=0.4
Total (95% CI) 2973 3204 100.0 0.51 [ 0.28, 0.91 ]
Total events: 46 (Three days), 103 (5-10 days)
Test for heterogeneity chi-square=29.30 df=17 p=0.03 I² =42.0%
Test for overall effect z=2.30 p=0.02
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Analysis 01.15. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 15 Gastrointestinal
adverse effects
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 15 Gastrointestinal adverse effects
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
Gordin 1987a 0/32 1/30 0.3 0.31 [ 0.01, 7.40 ]
x Gordin 1987b 0/36 0/34 0.0 Not estimable
Gossius 1984 6/136 11/132 3.5 0.53 [ 0.20, 1.39 ]
Gossius 1985 3/50 7/64 2.0 0.55 [ 0.15, 2.01 ]
x Greenberg 1986 0/26 0/28 0.0 Not estimable
Hansen 1981 3/102 7/119 1.9 0.50 [ 0.13, 1.88 ]
Internordic 1988 24/239 26/240 9.8 0.93 [ 0.55, 1.57 ]
Marsh 1980 9/59 13/69 5.1 0.81 [ 0.37, 1.76 ]
Neringer 1992 11/228 19/235 5.9 0.60 [ 0.29, 1.23 ]
Piipo 1990 17/197 11/197 5.7 1.55 [ 0.74, 3.21 ]
Pitkajarvi 1990 8/174 6/171 3.0 1.31 [ 0.46, 3.70 ]
Richards 1984 5/92 9/86 3.0 0.52 [ 0.18, 1.49 ]
Sandberg 1985 4/102 6/100 2.2 0.65 [ 0.19, 2.25 ]
Trienekens 1989 22/161 34/166 10.9 0.67 [ 0.41, 1.09 ]
Tsugawa 1999 2/45 3/50 1.1 0.74 [ 0.13, 4.23 ]
Subtotal (95% CI) 1679 1721 54.4 0.77 [ 0.61, 0.97 ]
Total events: 114 (Three days), 153 (5-10 days)
Test for heterogeneity chi-square=7.96 df=12 p=0.79 I² =0.0%
Test for overall effect z=2.17 p=0.03
02 Different antibiotic therapy in each group
Bitsch 1985 6/158 3/152 1.8 1.92 [ 0.49, 7.56 ]
Cox 1992 7/101 10/99 3.7 0.69 [ 0.27, 1.73 ]
Guibert 1997 8/212 10/209 3.9 0.79 [ 0.32, 1.96 ]
Henry 1999 42/394 46/386 14.8 0.89 [ 0.60, 1.33 ]
Hooton 1991 7/49 8/47 3.7 0.84 [ 0.33, 2.13 ]
Iravani 1999 8/239 48/474 5.7 0.33 [ 0.16, 0.69 ]
Menday 2000 11/219 5/221 3.0 2.22 [ 0.78, 6.28 ]
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Stein 1987 12/109 5/100 3.2 2.20 [ 0.80, 6.03 ]
Stein 1992 11/197 18/207 5.8 0.64 [ 0.31, 1.32 ]
Subtotal (95% CI) 1678 1895 45.6 0.88 [ 0.60, 1.29 ]
Total events: 112 (Three days), 153 (5-10 days)
Test for heterogeneity chi-square=15.38 df=8 p=0.05 I² =48.0%
Test for overall effect z=0.64 p=0.5
Total (95% CI) 3357 3616 100.0 0.81 [ 0.67, 0.97 ]
Total events: 226 (Three days), 306 (5-10 days)
Test for heterogeneity chi-square=23.59 df=21 p=0.31 I² =11.0%
Test for overall effect z=2.27 p=0.02
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Analysis 01.16. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 16 Skin adverse
effects
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 16 Skin adverse effects
Study Three-days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
Gordin 1987a 0/32 3/30 2.7 0.13 [ 0.01, 2.49 ]
Gordin 1987b 1/36 1/34 2.9 0.94 [ 0.06, 14.51 ]
Gossius 1984 4/136 23/132 8.5 0.17 [ 0.06, 0.47 ]
Gossius 1985 0/50 7/64 2.8 0.08 [ 0.00, 1.45 ]
x Greenberg 1986 0/26 0/28 0.0 Not estimable
x Hansen 1981 0/102 0/119 0.0 Not estimable
Internordic 1988 6/239 12/240 8.9 0.50 [ 0.19, 1.32 ]
Marsh 1980 2/59 2/69 4.8 1.17 [ 0.17, 8.05 ]
Neringer 1992 16/228 28/235 10.9 0.59 [ 0.33, 1.06 ]
Piipo 1990 5/197 7/197 8.0 0.71 [ 0.23, 2.21 ]
Pitkajarvi 1990 3/174 2/171 5.3 1.47 [ 0.25, 8.71 ]
x Richards 1984 0/92 0/86 0.0 Not estimable
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Study Three-days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Sandberg 1985 1/102 0/100 2.3 2.94 [ 0.12, 71.37 ]
Trienekens 1989 3/161 6/166 6.9 0.52 [ 0.13, 2.03 ]
Subtotal (95% CI) 1634 1671 63.9 0.51 [ 0.34, 0.77 ]
Total events: 41 (Three-days), 91 (5-10 days)
Test for heterogeneity chi-square=10.98 df=10 p=0.36 I² =8.9%
Test for overall effect z=3.17 p=0.002
02 Different antibiotic therapy in each group
Bitsch 1985 0/158 2/152 2.5 0.19 [ 0.01, 3.98 ]
Guibert 1997 5/212 2/209 5.8 2.46 [ 0.48, 12.56 ]
Henry 1999 27/394 6/386 9.4 4.41 [ 1.84, 10.56 ]
Iravani 1999 3/239 10/474 7.3 0.59 [ 0.17, 2.14 ]
Menday 2000 2/219 7/221 6.1 0.29 [ 0.06, 1.37 ]
Stein 1987 0/109 7/100 2.8 0.06 [ 0.00, 1.06 ]
Stein 1992 0/197 1/207 2.3 0.35 [ 0.01, 8.54 ]
Subtotal (95% CI) 1528 1749 36.1 0.69 [ 0.21, 2.28 ]
Total events: 37 (Three-days), 35 (5-10 days)
Test for heterogeneity chi-square=19.87 df=6 p=0.003 I² =69.8%
Test for overall effect z=0.61 p=0.5
Total (95% CI) 3162 3420 100.0 0.62 [ 0.36, 1.06 ]
Total events: 78 (Three-days), 126 (5-10 days)
Test for heterogeneity chi-square=37.71 df=17 p=0.003 I² =54.9%
Test for overall effect z=1.75 p=0.08
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Analysis 01.17. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 17 CNS adverse
effects
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 17 CNS adverse effects
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
Gordin 1987a 0/32 1/30 0.6 0.31 [ 0.01, 7.40 ]
x Gordin 1987b 0/36 0/34 0.0 Not estimable
Gossius 1984 4/136 7/132 4.2 0.55 [ 0.17, 1.85 ]
Gossius 1985 1/50 3/64 1.2 0.43 [ 0.05, 3.98 ]
x Greenberg 1986 0/26 0/28 0.0 Not estimable
x Hansen 1981 0/102 0/119 0.0 Not estimable
Internordic 1988 5/239 15/240 6.2 0.33 [ 0.12, 0.91 ]
Marsh 1980 3/59 4/69 2.9 0.88 [ 0.20, 3.76 ]
Neringer 1992 11/228 14/235 10.4 0.81 [ 0.38, 1.75 ]
Piipo 1990 4/197 1/197 1.3 4.00 [ 0.45, 35.47 ]
Pitkajarvi 1990 2/174 3/171 1.9 0.66 [ 0.11, 3.87 ]
Richards 1984 1/92 2/86 1.1 0.47 [ 0.04, 5.06 ]
Trienekens 1989 5/161 0/166 0.7 11.34 [ 0.63, 203.42 ]
Tsugawa 1999 0/45 2/50 0.7 0.22 [ 0.01, 4.50 ]
Subtotal (95% CI) 1577 1621 31.2 0.67 [ 0.43, 1.04 ]
Total events: 36 (Three days), 52 (5-10 days)
Test for heterogeneity chi-square=9.70 df=10 p=0.47 I² =0.0%
Test for overall effect z=1.79 p=0.07
02 Different antibiotic therapy in each group
Cox 1992 11/101 18/99 12.6 0.60 [ 0.30, 1.20 ]
Guibert 1997 4/212 2/209 2.2 1.97 [ 0.37, 10.65 ]
Henry 1999 38/394 40/386 34.5 0.93 [ 0.61, 1.42 ]
Hooton 1991 5/49 5/47 4.5 0.96 [ 0.30, 3.10 ]
Menday 2000 1/219 3/221 1.2 0.34 [ 0.04, 3.21 ]
Stein 1987 5/109 4/100 3.7 1.15 [ 0.32, 4.15 ]
Stein 1992 13/197 11/207 10.1 1.24 [ 0.57, 2.71 ]
Subtotal (95% CI) 1281 1269 68.8 0.91 [ 0.68, 1.23 ]
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Total events: 77 (Three days), 83 (5-10 days)
Test for heterogeneity chi-square=3.69 df=6 p=0.72 I² =0.0%
Test for overall effect z=0.60 p=0.5
Total (95% CI) 2858 2890 100.0 0.83 [ 0.65, 1.06 ]
Total events: 113 (Three days), 135 (5-10 days)
Test for heterogeneity chi-square=14.61 df=17 p=0.62 I² =0.0%
Test for overall effect z=1.50 p=0.1
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Analysis 01.18. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 18 Vaginal discharge
as an adverse effect of therapy
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 18 Vaginal discharge as an adverse effect of therapy
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
x Gordin 1987a 0/32 0/30 0.0 Not estimable
Gordin 1987b 1/36 2/34 2.9 0.47 [ 0.04, 4.97 ]
Gossius 1984 0/136 3/132 1.9 0.14 [ 0.01, 2.66 ]
x Gossius 1985 0/50 0/64 0.0 Not estimable
Greenberg 1986 0/26 1/28 1.6 0.36 [ 0.02, 8.42 ]
x Hansen 1981 0/102 0/119 0.0 Not estimable
Neringer 1992 5/228 2/235 6.1 2.58 [ 0.51, 13.15 ]
Pitkajarvi 1990 0/174 4/171 1.9 0.11 [ 0.01, 2.01 ]
Richards 1984 0/92 1/86 1.6 0.31 [ 0.01, 7.55 ]
Sandberg 1985 4/102 5/100 9.8 0.78 [ 0.22, 2.84 ]
Trienekens 1989 2/161 1/166 2.8 2.06 [ 0.19, 22.52 ]
Subtotal (95% CI) 1139 1165 28.7 0.75 [ 0.35, 1.59 ]
Total events: 12 (Three days), 19 (5-10 days)
Test for heterogeneity chi-square=6.59 df=7 p=0.47 I² =0.0%
Test for overall effect z=0.74 p=0.5
02 Different antibiotic therapy in each group
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Cox 1992 1/101 4/99 3.4 0.25 [ 0.03, 2.15 ]
Guibert 1997 9/212 8/209 18.7 1.11 [ 0.44, 2.82 ]
Henry 1999 14/394 15/386 31.8 0.91 [ 0.45, 1.87 ]
Hooton 1991 2/49 5/47 6.4 0.38 [ 0.08, 1.88 ]
Iravani 1999 0/239 5/474 1.9 0.18 [ 0.01, 3.24 ]
Stein 1987 1/109 2/100 2.9 0.46 [ 0.04, 4.98 ]
Stein 1992 2/197 5/207 6.1 0.42 [ 0.08, 2.14 ]
Subtotal (95% CI) 1301 1522 71.3 0.73 [ 0.45, 1.17 ]
Total events: 29 (Three days), 44 (5-10 days)
Test for heterogeneity chi-square=4.30 df=6 p=0.64 I² =0.0%
Test for overall effect z=1.31 p=0.2
Total (95% CI) 2440 2687 100.0 0.73 [ 0.49, 1.10 ]
Total events: 41 (Three days), 63 (5-10 days)
Test for heterogeneity chi-square=10.88 df=14 p=0.70 I² =0.0%
Test for overall effect z=1.51 p=0.1
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Analysis 01.19. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 19 Other adverse
effects
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 19 Other adverse effects
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Same antibiotic therapy in each group
x Gordin 1987a 0/32 0/30 0.0 Not estimable
x Gordin 1987b 0/36 0/34 0.0 Not estimable
Gossius 1984 0/136 1/132 0.9 0.32 [ 0.01, 7.87 ]
Gossius 1985 0/50 1/64 0.9 0.42 [ 0.02, 10.21 ]
x Greenberg 1986 0/26 0/28 0.0 Not estimable
x Hansen 1981 0/102 0/119 0.0 Not estimable
Internordic 1988 15/239 14/240 18.3 1.08 [ 0.53, 2.18 ]
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Marsh 1980 3/59 2/69 3.0 1.75 [ 0.30, 10.15 ]
Neringer 1992 5/228 7/235 7.1 0.74 [ 0.24, 2.29 ]
Piipo 1990 6/197 4/197 5.9 1.50 [ 0.43, 5.23 ]
Pitkajarvi 1990 8/174 5/171 7.6 1.57 [ 0.52, 4.71 ]
Richards 1984 2/92 3/86 2.9 0.62 [ 0.11, 3.64 ]
Sandberg 1985 1/102 1/100 1.2 0.98 [ 0.06, 15.46 ]
Trienekens 1989 8/161 10/166 11.2 0.82 [ 0.33, 2.04 ]
Tsugawa 1999 2/45 0/50 1.0 5.54 [ 0.27, 112.47 ]
Subtotal (95% CI) 1679 1721 60.0 1.05 [ 0.71, 1.55 ]
Total events: 50 (Three days), 48 (5-10 days)
Test for heterogeneity chi-square=4.16 df=10 p=0.94 I² =0.0%
Test for overall effect z=0.25 p=0.8
02 Different antibiotic therapy in each group
Guibert 1997 18/212 18/209 23.4 0.99 [ 0.53, 1.84 ]
Henry 1999 9/394 7/386 9.6 1.26 [ 0.47, 3.35 ]
Menday 2000 3/219 9/221 5.5 0.34 [ 0.09, 1.23 ]
Stein 1987 1/109 2/100 1.6 0.46 [ 0.04, 4.98 ]
Subtotal (95% CI) 934 916 40.0 0.87 [ 0.53, 1.42 ]
Total events: 31 (Three days), 36 (5-10 days)
Test for heterogeneity chi-square=3.07 df=3 p=0.38 I² =2.3%
Test for overall effect z=0.55 p=0.6
Total (95% CI) 2613 2637 100.0 0.98 [ 0.72, 1.32 ]
Total events: 81 (Three days), 84 (5-10 days)
Test for heterogeneity chi-square=7.56 df=14 p=0.91 I² =0.0%
Test for overall effect z=0.15 p=0.9
0.001 0.01 0.1 1 10 100 1000
Favours three days Favours 5-10 days
62Duration of antibacterial treatment for uncomplicated urinary tract infection in women (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Analysis 01.20. Comparison 01 Three days versus 5-10 day antibiotic therapy, Outcome 20 Patients with any
adverse effects during treatment by antibiotic class (same drug)
Review: Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Comparison: 01 Three days versus 5-10 day antibiotic therapy
Outcome: 20 Patients with any adverse effects during treatment by antibiotic class (same drug)
Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Quinolones
Internordic 1988 46/239 58/240 13.3 0.80 [ 0.57, 1.12 ]
Neringer 1992 57/228 73/235 15.1 0.80 [ 0.60, 1.08 ]
Piipo 1990 28/197 22/197 8.4 1.27 [ 0.75, 2.15 ]
Trienekens 1993 26/199 29/193 9.1 0.87 [ 0.53, 1.42 ]
Tsugawa 1999 4/45 5/50 2.1 0.89 [ 0.25, 3.11 ]
Subtotal (95% CI) 908 915 48.0 0.86 [ 0.72, 1.04 ]
Total events: 161 (Three days), 187 (5-10 days)
Test for heterogeneity chi-square=2.56 df=4 p=0.63 I² =0.0%
Test for overall effect z=1.55 p=0.1
02 Beta-lactams
Gordin 1987b 2/36 3/34 1.1 0.63 [ 0.11, 3.54 ]
Greenberg 1986 0/26 1/28 0.4 0.36 [ 0.02, 8.42 ]
Hansen 1981 3/102 7/119 1.9 0.50 [ 0.13, 1.88 ]
Hovelius 1985 2/27 1/33 0.6 2.44 [ 0.23, 25.53 ]
Marsh 1980 17/59 22/69 8.3 0.90 [ 0.53, 1.53 ]
Pitkajarvi 1990 21/174 20/171 7.4 1.03 [ 0.58, 1.83 ]
Richards 1984 8/92 15/86 4.4 0.50 [ 0.22, 1.12 ]
Sandberg 1985 10/102 12/100 4.6 0.82 [ 0.37, 1.80 ]
Subtotal (95% CI) 618 640 28.7 0.82 [ 0.61, 1.11 ]
Total events: 63 (Three days), 81 (5-10 days)
Test for heterogeneity chi-square=3.94 df=7 p=0.79 I² =0.0%
Test for overall effect z=1.28 p=0.2
03 TMP/sulfonamides
Gordin 1987a 0/32 5/30 0.4 0.09 [ 0.00, 1.48 ]
Gossius 1984 12/136 37/132 6.9 0.31 [ 0.17, 0.58 ]
Gossius 1985 4/50 18/64 3.0 0.28 [ 0.10, 0.79 ]
Trienekens 1989 40/161 51/166 13.0 0.81 [ 0.57, 1.15 ]
Subtotal (95% CI) 379 392 23.3 0.40 [ 0.19, 0.88 ]
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Study Three days 5-10 days Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
Total events: 56 (Three days), 111 (5-10 days)
Test for heterogeneity chi-square=11.44 df=3 p=0.010 I² =73.8%
Test for overall effect z=2.30 p=0.02
Total (95% CI) 1905 1947 100.0 0.76 [ 0.63, 0.92 ]
Total events: 280 (Three days), 379 (5-10 days)
Test for heterogeneity chi-square=22.63 df=16 p=0.12 I² =29.3%
Test for overall effect z=2.87 p=0.004
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